CLINICAL STUDY PROTOCOL
Study Title: A Phase 2, Open -label, Translational Biology  Study  of 
Momelotinib in Transfusion- Dependent Subjects with Primary  
Myelofibrosis ( PMF) or Post-polycythemia Vera or Post -essential 
Thrombocy themia My elofibrosis (Post -PV/ET MF)
Sponsor: [COMPANY_009] Sciences, Inc.
[ADDRESS_516730]
Foster City , CA [ZIP_CODE] [LOCATION_003]
IND Number :
EudraCT Number :101155
Not Applicable
Indication: Primary  Myelofibrosis ( PMF) or Post - polycythemia Vera or Post -
essential Thrombocy themia My elofibrosis (Post- PV/ET MF)
Protocol ID: GS-US-352-1672
Clinical Program 
Manager :Name: [CONTACT_409768]: (650) 378 -
3104
[COMPANY_009] Medical Monitor : Name: [CONTACT_409769], MD, PhD
Telephone: (650) 522 -5377
Protocol Version/Date: Original : 18May [ADDRESS_516731] or Independent Ethics Committee. The information is only  to be used by y ou in 
connection with authorized clinical studies of the investigational drug described in the protocol. 
You will not disclose any of the information to others without wr itten authorization from 
[COMPANY_009] Sciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may  be administered.

Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516732] OF IN- TEX T TA BLES ........................................................................................................................................ 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 13
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.2. Mom elotinib (MMB) ............................................................................................................................. 17
1.2.1. General Information ............................................................................................................. 17
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 17
1.2.3. Clinical Trials of Momelotinib ............................................................................................. 21
1.2.4. Special Risk .......................................................................................................................... 21
1.3. Rationale for This Study ........................................................................................................................ 21
1.4. Com pliance ............................................................................................................................................ 22
2. OBJECTIVES ..................................................................................................................................................... 23
3. STUDY DESIGN ................................................................................................................................................ 24
3.1. Endpoint ................................................................................................................................................. 24
3.2. Study Design .......................................................................................................................................... 24
3.3. Study Treatments ................................................................................................................................... 24
3.4. Duration of Treatment ............................................................................................................................ 24
3.5. Discontinuation Criteria ......................................................................................................................... 24
3.6. Source Data ............................................................................................................................................ 24
3.7. Biomarker Testing .................................................................................................................................. 25
3.7.1. Biomarker Samples to Address the Study Objectives: ......................................................... [ADDRESS_516733] Selection ............................................................................................ 28
4.2. Inclusion Criteria .................................................................................................................................... 28
4.3. Exclusion Criteria ................................................................................................................................... 29
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 30
5.1. Enrollment and Treatment Assignment .................................................................................................. 30
5.2. Description and Handling of MMB ........................................................................................................ 30
5.2.1. Form ulation .......................................................................................................................... 30
5.2.2. Packaging and Labeling ....................................................................................................... 30
5.2.3. Storage and Handling ........................................................................................................... 30
5.3. Dosage and Administration of MMB ..................................................................................................... 30
5.3.1. Starting Dose ........................................................................................................................ 30
5.3.2. Discontinuing or Interrupting MMB Treatment ................................................................... 31
5.3.3. MMB Dose Adjustments and Dose Interruption .................................................................. 31
5.3.4. Dose Adjustments for Thrombocytopenia ............................................................................ 31
5.3.5. Dose Adjustments for Neutropenia ...................................................................................... 32
5.3.6. Dose Adjustments for Non -hematologic Toxicities ............................................................. 32
5.3.7. Dose Adjustments Based on Response ................................................................................. 32
5.3.8. Dose Adjustments for Other Toxicities ................................................................................ 33
5.4. Prior and Concomitant Medications ....................................................................................................... 33
5.4.1. Restricted Medications ......................................................................................................... 33
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516734] Cancer Resistance Protein (BCRP) Substrates .......................................................... 33
5.4.4. Organic Anion -Transporting Polypeptide (OATP) Inhibitors .............................................. [ADDRESS_516735] Enrollment and Treatment Assignment ..................................................................................... 35
6.2. Study Procedure Descriptions ................................................................................................................ 35
6.2.1. Informed Consent ................................................................................................................. 35
6.2.2. Medical History .................................................................................................................... 35
6.2.3. Medication History ............................................................................................................... 35
6.2.4. Physical Examination and Myelofibrosis Symptom Assessment ......................................... 35
6.2.5. Vital Signs ............................................................................................................................ 36
6.2.6. Ophthalmic Examinations .................................................................................................... 36
6.2.7. Laboratory Assessments ....................................................................................................... 36
6.2.8. Biomarker Samples .............................................................................................................. 37
6.2.9. Pharm acokinetics ................................................................................................................. 38
6.2.10. Patient -reported Outcomes Assessments (PRO) .................................................................. [ADDRESS_516736]-treatment Assessments ................................................................................................................... 46
6.7.1. Early Study Drug Discontinuation ....................................................................................... 46
6.7.2. 30-Day Follow -up Assessments ............................................................... ............................ 47
6.8. Criteria for Discontinuation of Study Treatment .................................................................................... 48
6.9. End of Study ........................................................................................................................................... 48
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 49
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 49
7.1.1. Adverse Events ..................................................................................................................... 49
7.1.2. Serious Adverse Events ........................................................................................................ 49
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 50
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 51
7.2.1. Assessment of Causality for MMB and Procedures ............................................................. 51
7.2.2. Assessment of Severity ........................................................................................................ 51
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 52
7.3.1. Adverse Events ..................................................................................................................... 52
7.3.2. Serious Adverse Events ........................................................................................................ 52
7.4. [COMPANY_009] Reporting Requirements ............................................................................................................. 54
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 54
7.6. Toxicity Management ............................................................................................................................ 54
7.7. Special Situations Reports ...................................................................................................................... 55
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516737] (IRB) Review and Approval ..................................................... [ADDRESS_516738] Accountability and Return .............................................................. 66
9.1.8. Inspections ............................................................................................................................ 66
9.1.9. Protocol Compliance ............................................................................................................ 66
9.2. Sponsor Responsibilities ........................................................................................................................ 66
9.2.1. Protocol Modifications ......................................................................................................... 66
9.2.2. Study Report and Publications ............................................................................................. 67
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 67
9.3.1. Payment Reporting ............................................................................................................... 67
9.3.2. Access to Information for Monitoring .................................................................................. 67
9.3.3. Access to Information for Auditing or Inspections .............................................................. 68
9.3.4. Study Discontinuation .......................................................................................................... 68
10. REFERENCES ................................................................................................................................................... 69
11. APPENDICES .................................................................................................................................................... 72
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 73
Appendix 2. Study Procedures Table .......................................................................................................... 74
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 77
Appendix 4. Dynamic International Prognostic Scoring System (DIPSS) for Primary 
Myelofibrosis .......................................................................................................................... 80
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516739] OF IN -TEXT TABLES
Table 3-1. Biomarker Specimens and Tests to Address Study Objectives .............................................. 26
Table 5-1. MMB Dose Reductions for Subjects with Thrombocytopenia ............................................... 31
Table 5-2. Doses for Restarting MMB after Withholding Treatment for Toxicity .................................. 32
Table 6-1. An alytes .................................................................................................................................. 37
Table 7-1. Grading of Adverse Event Severity ........................................................................................ 52
Table 7-2. Grading of Anemia (Hgb) Severity ........................................................................................ [ADDRESS_516740] 90% CIs for various response rates .............................................................................. 62
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516741].
Foster City, CA [ZIP_CODE]
Study Title: A Phase 2, Open- label, Transl ational Biology  Study  of Momelotinib in 
Transfusion- Dependent Subjects with Primary  Myelofibrosis ( PMF) or 
Post-polycythemia Vera or Post -essential Thrombocy themia 
Myelofibrosis (Post -PV/ET MF) 
IND Number:
EudraCT Number:101155
Not Applicable
Study Centers 
Planned:Approximately  20centers in North America
Objectives: The primary  objective of this study  is:
To determine the transfusion independence response rate for 
transfusion dependent myelofibrosis ( MF)subjects treated with 
momelotinib (MMB )
The secondary  objectives of this study  are: 
To evaluate baseline levels and changes in markers of iron 
metabolism in transfusion dependent MF subjects treated with 
MMB
To assess inhibition of JAK1/2 in transfusion dependent MF 
subjects treated with MMB 
To evaluate MMB pharmacokinetics (PK) in transfusion dependent  
MF subjects
To evaluate changes in circulating cy tokine and inflammatory  
markers in transfusion dependent MF subjects treated with MMB   
Study Design: This is a single -arm, open -label study of MMB in transfusion-
dependent subjects with PMF or Post -PV/ET MF.  Subjects will receive 
MMB for 24 weeks ( 7 day s) on study .
After completion of the 24 week ( 7 day s) treatment phase visit 
procedures , subjects who respond to treatment, at the investigator’s 
discretion, will have the option of maintenance therap y with MMB on 
Study  GS
-US-352- 1154 at the MMB dose they  tolerated and/or derived 
clinical benefit from during the 24 -
week treatment period.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 7 18May 2015Number of 
Subjects Planned:Approximately  40
Target Population: Subjects with PMF orPost-PV/ET MF who are transfusion dependent
Duration of 
Treatment:Theplanned duration of study  treatment is 24 weeks (
±7 day s). 
Diagnosis and 
Main Eligibility  
Criteria:Inclusion Criteria:
1)Age ≥ 18 y ears old
2)Diagnosis of PMF or Post PV/ET -MF
3)Requires my elofibrosis therapy , in the opi[INVESTIGATOR_871]
4)High risk or intermediate -2 risk defined by [CONTACT_409748] S ystem(DIPSS)
orintermediate -1 
risk defined b y DIPSS and associated with s ymptomatic 
splenomegaly  and/or hepatomegal y
5) Transfusion dependent at baselin e, defined as ≥ 4U RBC transfusion 
in the [ADDRESS_516742] dose of MMB
6)
Acceptable organ function as evidenced by  [CONTACT_716]:
a)Platelet Count ≥ 50 x 109/L 
b) AST/SGOT and ALT/SGPT ≤ 3 x upper limit of normal (ULN)
or  AST /SGOT or ALT/SGPT ≤ 5 x UL N if liver is involved by  
[CONTACT_409749] 
c)Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance 
of ≥ 60mL /min 
d)Direct bilirubi n ≤ 2.[ADDRESS_516743]
7)Peripheral blood blast count < 20% 
8)
Expected Life expectancy  of > 24 weeks
9) A negative serum pregnancy  test for female subjects (unless 
surgically  sterile or greater than two y ears postmenopausal) 
10) Male subjects and female subjects of childbearing potential who 
engage in heterosexual intercourse must agree to use protocol 
specified method(s) of contraception as described in Appendix 3
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 8 18May 201511)Lactating females must agree to discontinue nursing before MMB
administration
12)Able to understand and willing to sign the informed consent form
Exclusion Criteria:
1)Prior splenectom y
2) S plenic irradiation within 3months prior to the first dose of MMB
3)Prior treatment with MMB
4) Known positive status of human immunodeficiency  virus ( HIV)
5) Chronic active or acute viral hepatitis A, B, or C infection (testing 
required for hepatitis B and C), or hepatitis B or C carrier
6)Use of strong CYP3A4 inducer within [ADDRESS_516744] dose 
of MMB
7)Uncontrolled intercur rent illness including, but not limited to, active 
uncontrolled infection, uncontrolled cardiac arrh ythmia, or 
psychiatric illness/social situation that would limit compliance with 
study  requirements as judged b y treating ph ysician
8)History  of a prior diagn osis of any  malignancy  other than PMF or 
Post PV/ET -MF except for the following: adequately treated local 
basal cell or squamous cell carcinoma of the skin, cervical 
carcinoma in situ, superficial bladder cancer, as ymptomatic prostate 
cancer without known metastatic disease and with no requirement 
for therap y or requiring only  hormonal therap y and with normal 
prostate specific antigen for >1 year prior to 
enrollment , or any  other 
cancer that has been in complete remission without treatment for 
≥ 5years pri or to enrollment .
9)Treatment with a JAK inhibitor within 21 day s of the planned 
firstdose of MMB
10)Documented m yocardial infarction or unstable/uncontrolled cardiac 
disease ( eg, unstable angina, congestive heart failure [[LOCATION_001] 
Heart Association > Class III]) within 6 months of randomization
11) Presence of peripheral neuropathy ≥ CTCAE Grade 2
12)Unwilling or unable to undergo Magnetic Resonance Imaging
(MRI )per requirements in Section 
[IP_ADDRESS]
13)Unwilling to consent to genomics sampling
14)Pregnant or breast -feeding
15)Known hy persensitivity  to the study  investigational medicinal 
products, the metabolites, or formulation excipi[INVESTIGATOR_409734] (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 9 18May 2015Study  Procedures/
Frequency :Subjects may  participate in the study  for up to 28 weeks. This consists 
of up to 4 weeks (28 days) of screening and 24 weeks of stud y 
treatment.  Study  visits will be completed at 2 weeks and 4 weeks 
following initiation of MMB treatment, and thereafter every 4 weeks
until week 24 . 
During the screening period, subjects will undergo an MRI  to assess 
spleen volume and l iver iron concentration (LIC), bone marrow biops y, 
and blood sampling for clinical and pharmacod ynamics tests.  Subjects 
will receive an elec tronic diary  (eDiary ) for dail y completion of the 
modified Myeloproliferative Neoplasm Sy mptom Assessment Form 
Total Sy mptom Score (MPNSAF TSS).  Subjects will complete the 
modified MPNSAF TSS daily  through screening and [ADDRESS_516745]’s 
last dose of MMB.  Subjects completing the Week [ADDRESS_516746], Dose, 
and Mode of 
Administration:The starting dose of MMB for all subjects will be 200 mg in a single 
tablet. MMB will be orally  self-administered once daily , in the morning, 
and thereafter at approximately  the same time each day . The dose of 
MMB may  be withheld or adjusted according to t he criteria in the 
protocol.
Reference Therapy, 
Dose, and Mode of 
Administration:None
Criteria for 
Evaluation:
Safety : The overall safet y profile of MMB will be characterized by  [CONTACT_941] t ype, 
frequency , severity , timing of onset, duration, and relationship to MMB 
of an y adverse events (AEs) or abnormalities of laboratory tests; serious 
adverse events (SAEs); or AEs leading to discontinuation of MMB .
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 10 18May 2015Efficacy : Primary Endpoints
The primary  endpoint is t ransfusion independence response rate b y 
Week 24, defined as becoming transfusion independent for ≥ [ADDRESS_516747] is considered as transfusion independent 
on study  if no RBC transfusio noccurs in an y 12 weeks during the 24 -
week treatment period.
Secondary Endpoints
The s econdary  endpoints are:
Transfusion response rate by [CONTACT_10585] 24, defined as becoming not 
transfusion dependent for ≥ 8weeks at an y time on study
Baseline and change in marker sof anemia (eg, hepcidin, ferritin)
Change in pharmacod ynamic sbiomarker pSTAT3
Splenic response rate at Week 24, defined as ≥35% reduction in 
spleen volume from baseline as measured b y MRI
Response rate in total s ymptom score (TSS) at Week 24 ,defined as 
achieving a 
≥ 50% reduction from baseline in TSS as measured by  
[CONTACT_409750]
Pharmacokinetic s parameters (C max, Clast, Ctauand AUC last, if 
available) for MMB 
Change in circulating cy tokine and inflammatory  markers (eg, IL -6, 
IL-8, IFN gamma, TNF alpha)
Exploratory Endpoints
The exploratory  endpoints are:
Baseline and change in markers of orthogonal or parallel signaling 
pathway s (eg, RAS/MAPK, PI 3K/AKT)
Baseline and change in gene expression profiles in whole blood and 
somatic mutations in whole blood
Baseline and change in immune subsets in whole blood
Change in exploratory  pharmacod ynamics markers of signaling 
mediated b y JAK1 and/or JAK2 (eg, pSTAT1, pSTAT5, and 
pSTAT6)
Pharmacokinetics: B
lood samples will be collected at the time points specified in the 
protocol. 
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 11 18May 2015Statistical Methods: The Safet y Analysis Set includes all subjects who receive ≥ [ADDRESS_516748]’s characteristics, efficacy  and safet y 
endpoints, and study  treatment administration.
The Biomarker Anal ysis Set consists of all subjects in the Safety  
Analy sis Set who have the necessary  baseline and on- study  
measurements to provide interpretable results for the specific 
parameters of interest. The Biomarker Analy sis Set will be used for 
biomarkers and the correlation analy ses between biomarkers and 
efficacy  clinical endpoints.
The PK Anal ysis Set consists of all subjects in the Safety  Anal ysis Set 
who have the necessary  baseline and on- study  measurements to provide 
interpretable results for the specific parameters of interest.
Subject demographic and baseline characteristics will be listed and 
summarized as appropriate . 
Transfusion independence response rate, transfusion response rate, 
splenic response rate and TSS response rate will be presented with 
corresponding 2
-sided 90% exact CI s using the binomial distribution. 
The number and percentage of subjects in each response category  
(complete remission [ CR] or partial remi ssion [ PR]) will also be 
summarized. Subjects who do not have sufficient baseline or on -study  
tumor assessment to characterize response will be counted as 
non-responders.
All safet y data collected on or after the date that MMB was 
firstdispensed up to the date of last dose of MMB plus 30 day s will be 
summarized. Data for the pretreatment will be included in data listings.
The baseline levels, and changes in biomarker levels over time from 
baseline level, will be evaluated. Descriptive statistics will be pr ovided 
at each sampling time, and by  [CONTACT_409751], as 
appropriate. Exploratory  graphics, such as side -by-side boxplots will 
also be generated.
Univariate and multivariate stat istical techniques may
 be explored to 
evaluate the association of baseline biomarkers and changes in 
biomarkers with clinical outcomes as appropriate. Due to the 
exploratory  nature of the end points, no formal hypothesis testing will 
be conducted.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516749] size. A 
sample size of 40 subjects is considered adequate for this exploratory  
study .
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 13 18May 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
ADM E absorption, distribution, metabolism, andelimination
AE adverse event
ALT alanine aminotransferase 
ANC absolute neutrophil counts 
AST aspartate aminotransferase
AUC area under theplasma/serum/peripheral blood mononuclear cell
concentration versus time curve
AUC last AUC up to the last measurable concentration
BCRP Breast cancer resistant protein
BUN blood urea nitrogen 
CBC complete blood count 
CI confidence interval 
CL cr creatinine clearance
Cmax themaximum observed serum/plasma/PBMC concentration of drug
Clast last observed quantifiable concentration
CML Chronic mylogenous leukemia
CR complete remission
CRF case report form(s)
CRO contract (orclinical) research organization
CRP C-Reactive Protein
CSR Clinical Study Report
CT computed tomography/computed axial tomography scan 
CTCAE Common Term inology Criteria forAdverse Events 
CYP450 cytochrome P450
Da Dalton
DIPSS Dynamic International Prognostic Scoring System
DSPH Drug Safety andPublic Health
ECG electrocardiogram
eCRF Electronic case report form(s)
EDC Electronic data capture
eDiary Electronic diary
EPO Erythropoietin
ESDD Early Study Drug Discontinuation
ET Essential thrombocythemia
FDA ([LOCATION_002]) Food andDrug Administration
FSH Follicle stimulating hormone
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 14 18May 2015GLOSSARY OFABBREVIA TIONS AND DEFINITIO NSOFTERMS (CONTINU ED)
GCP Good Clinical Practice (guidelines) 
GD Gestational Days
[COMPANY_009] [COMPANY_009] Sciences, Inc.
GLP Good Laboratory Practice (guidelines)
hCG human chorionic gonadotropin
HDP E high-density polyethylene
Hgb hemoglobin
HIV human immunodeficiency virus
HSPC hematopoietic stem/progenitor cells
IB investigator’s brochure
ICH International Conference onHarmonisation
IEC independent ethics committee
IND Investigational New Drug (Application)
IRB institutional revie wboard 
IUD intrauterine device
IWG-MRT International Working Group for Myelofibrosis Research and Treatment
IWRS interactive webresponse system
JAK Janus kinase
LIC Liver iron concentration
LLN lowerlimit ofthenormal range 
m meter
MCV Mean cell volume
medDRA Medical dictionary for regulatory activities
MF myelofibrosis
mg milligram
MMB mom elotinib
MPL megakaryocyte proliferative ligand
MPN myeloproliferative neoplasm
MPNSA FTSS Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom
Score
MRI magnetic resonance image 
N Number in population
n Number in data
NOAEL noobserved adverse effect level
NOEL No observed effect level
PBMC peripheral blood mononuclear  cell
PD progressive disease
PGIC Patient Global Impression ofChange
PK Pharmacokinetic
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 15 18May 2015GLOSSARY OFABBREVIA TIONS AND DEFINITIO NSOFTERMS (CONTINU ED)
PMF primary myelofibrosis
PR partial remission
PRO patien t-reported outcome
PV polycythemia vera
QD once daily
RBC Red blood cell
SADR Serious adverse drug reactions
SAE serious adverse event
SAP Statistical Analysis Plan
SOP standard operating procedure
STAT Signal Transducer and Activator of Transcription
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction 
tmaxThetime (observed time point) ofCmax
t½Anestimate oftheterminal elimination half-lifeofthedrug
TYK Tyrosine kinase
U Units
ULN upper limit ofthenorm alrange 
WHO World Health Organization
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 16 18May [ZIP_CODE]. INTRODUCTION
1.1. Background
Myeloproliferative neoplasm (MPN) is classified by  [CONTACT_38375] (WHO) into 
eight categories that include poly cythemia vera (PV), essential thrombocythemia (ET), primary  
myelofibrosis ( PMF ), chronic my elogenous leukemia (CML ), chronic neutr ophilic leukemia, 
chronic eosinophilic leukemia, mast cell disease, and MPN unclassifiable {[ZIP_CODE]} . Clonal 
hematopoiesis is a shared feature of the MPNs, with CML  characterized by  [CONTACT_409752], the product of a reciprocal translocation between the long arms of 
chromosomes 9 and 22. This t ranslocation results in the formation of the BCR- ABL1 oncogene, 
the molecular pathogenetic event of CML {[ZIP_CODE]} . Subsequently , a single acquired point 
mutation in the Janus kinase ( JAK)2 gene at codon 617, resulting in the substitution of valine for 
pheny lalanine (JAK2V617 F), was identified in patients with PV (~96%), ET (~50%), and 
myelofibrosis (~50%) { [ZIP_CODE] },{[ZIP_CODE] },{[ZIP_CODE] },{[ZIP_CODE] }. Positivity  for the JAK2V617F mutation 
results in constitutive activation of the downstream Signal Transducer and Activator of 
Transcription (STAT), cy tokine hy persensitivity , and formation of ery thropoietin -independent 
erythroid colonies { [ZIP_CODE]} .  
Since the discovery  of the JAK2V617F mutation in patients with MPN , additional mutations 
have been identified including signaling mutations that activate the thrombopoietin receptor 
(MPL ).  Somatic mutations of CAL R, the gene encoding calreticulin, have also been identified in 
patients with wild ty pe JAK2, as well as mut ations in epi[INVESTIGATOR_409735] {[ZIP_CODE]} .
Myelofibrosis is associated with a characteristic marrow stroma pattern, leukoery throblastosis, 
and elevated levels of inflammatory  cytokines. Patients may  experience anemia, leukopenia or 
leukocy tosis, thrombocy topenia or thrombocy tosis, constitutional sy mptoms, and extramedullary  
hematopoiesis resulting in hepatosplenomegal y{[ZIP_CODE] }. In a proportion of patients, 
myelofibrosis may  transform into acute leukemia {[ZIP_CODE]} . Treatment for PMF, and the 
phenoty pi[INVESTIGATOR_409736] -PV/ET MF, are principally  focused on s ymptom palliation, with 
allogeneic stem cell transplantation offering apotential cure for select patients {[ZIP_CODE]} .
Momelotinib (MMB) is a small molecule JAK1 and JAK2 inhibitor , with good selectivity over 
other JAK family  kinases (JAK3, TYK2) and excellent selectivity  over other ty rosine and 
serine/threonine kinases . In the phase 1/[ADDRESS_516750]-PV/ET MF (Study  CCL09101), the rate of spleen response, defined as ≥ 50% reduction 
in palpable splenomegal y lasting ≥8 weeks for baseline splenomegal y ≥ 10 cm plus resolution of 
palpable splenomegal y lasting ≥ 8 weeks for baseline splenomegal y > 5 to < 10 cm, was 33%.  
Anemia response, defined as a transfusion
-free interval of ≥ 12 weeks for baseline transfusion 
dependence, plus ≥ 2 g/dL rise in hemoglobin (Hgb) for baseline transfu sion independence and 
Hgb < 10 g/dL, was 41%.  Baseline transfusion dependence for Study  CCL09101 was defined as 
≥ 2 units (U) red blood cell ( RBC )transfusion in the [ADDRESS_516751] common Grade 3 or 4 
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 17 18May 2015treatment -related events reported b y ≥ 2 subjects on study were thrombocy topenia (24%), lipase 
increased (4%), neutropenia (3%), and anemia ( 2%).  Treatment -emergent peripheral neuropath y 
or sensory  neuropathy  adverse events were reported by 55 subjects (33%), with the neuropathy  
events categorized in 45 subjects (27%) as probably  or possibl y related to MMB. 
1.2. Momelotinib (MMB)
1.2.1. General Information
MMB dihy drochloride (N (cy anometh yl)-4-(2-(4-morpholinopheny lamino)py rimidin - 4-
yl)benzamide, CYT387, GS -0387) is a novel, weakly  basic, disubstituted py rimidine compound 
with a molecular weight of 487.38 daltons ( Da). The free base is poorly  soluble in water. MMB 
is presented for clinical administration as a dihy drochloride monohy drate salt. The 
dihydrochloride monohydrate salt shows kinetic solubility  in w ater at concentrations up to 
60mg/mL . MMB dihy drochloride is manufactured from a pyrimidine scaffold in a five -step 
process. 
In cellular assay s and in vitro, MMB was shown to be a potent and selective ATP -
competitive 
small -molecule inhibitor of JAK1 and JAK2, and is active at low nanomolar concentrations. 
MMB demonstrates marked dise ase-modify ing properties in ex vivo assay s of human ery throid 
cells from PVpatients and in a transgenic mouse model of my eloproliferative neoplasm. Kinase 
profiling of MMB indicates the compound is broadly  selective for JAK1 and JAK2 over other 
kinase enz ymes, including the closely  related JAK3 and ty rosine kinase (TYK) 2. MMB display s 
potent in vitro inhibitory  activity  against cells dependent on JAK.
For further information on MMB , refer to the investigator’s brochure (IB) for MMB. 
1.2.2. Preclinical Pharmacol ogy and Toxicology
[IP_ADDRESS]. Absorption, Distribution, Metabolism, and Elimination (ADME)
Equivalent mean maximal plasma concentrations of MMB (~700 ng/mL) and comparable 
elimination half -lives (~1h) were observed in both fed and fasted animals, consistent with 
previous data. There was however a notable prolongation in absorption in fed dogs with a 
delay ed T max(3h fed vs. 1h fasted). Furthermore, the AUC following dosing to feed dogs was 
approximately  double that seen in fasted animal studies suggesting that MMB s ystemic 
availability  is markedl y improved when the compound is administered postprandially.
Consistent with the moderate to high bioavailability seen in nonclinical species, MMB shows 
high permeability  in vitro across human Caco- [ADDRESS_516752] high permeability  across the intestinal mucosa in 
humans and high oral absorption in vivo. 
Data from plasma protein binding studies using rat and human plasma indicate that MMB binds 
extensively  to rat plasma proteins (~ 97%) and moderatel y to human plasma proteins (87% to 
92%). The mean human blood -to-plasma ratio was determined to be approximately  1.1, 
suggesting similar distribution between the cellular and plasma fr actions of blood. The rat 
blood -to-plasma ratio ranged from 0.6 to 0.8 indicating a lesser partitioning into blood cells.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 18 18May 2015The sy stemic clearance of MMB was low in rats and significantl y higher in dogs. The stead y 
state volume of distribution in both species substantially  exceeded total body  water. Following 
oral administration as the dihydrochloride salt, MMB showed high bioavailability in the rat 
(50%) and moderate bioavailability  in the dog (20%). The pharmacokinetic (PK)parameters in 
both the rat and dog indicated that MMB w as well absorbed. In the rat, less than 10% of an 
administered dose of MMB was recovered in the urine as parent compound suggesting that 
urinary  excretion is a minor clearance route for the parent compound.
The distribution of MMB into brain tissue was ass essed in Swiss outbred mice following 
intravenous administration (5 mg/kg). The brain -to-plasma ratio for MMB was determined to be 
0.075 and 0.215 at 5 and 60 minutes following MMB administration, respectively , suggesting 
low permeability  of MMB across the blood brain barrier.
Metabolite profiling has identified major putative metabolites from in vitro and in vivo studies. 
Metabolite M19 (GS -642112) was present in greater amounts in both rat (both dose levels) and 
dog plasma pools, than in the human plasma pool. Metabolites M15, M17, and M20 were present 
in greater amounts in the rat plasma pool (both dose levels), than in the human or dog plasma 
pools. Metabolite M21 (GS -644603) was present in human plasma at higher levels than that 
observed in rat plasma ( 20 mg/kg or 80 mg/kg doses, respectively ). Metabolite M21 was not 
observed in the dog plasma. M8 was not observed in either the rat or dog plasma pools. 
The ability  of the major drug- metabolizing cytochrome P40 (CYP450 )enzy mes (CYP1A2, 2A6, 
CYP2B6, CYP2C 9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5) to metabolize 
MMB was assessed with recombinant human CYP450 enzy mes (Supersomes ™) and human 
primary hepatocy tes.  MMB is primarily  metabolized by  [CONTACT_409753], including 
CYP3A, CYP2C8 and CYP2C19, wit h aldehy de oxidase also participating in metabolism to 
form the major, active metabolite M21.
The potential of MMB to impair the metabolism of other agents by  [CONTACT_409754]. The half- maximal inhibi tory concentration 
(IC50) of MMB on the five CYP isoforms investigated (CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4) was greater than [ADDRESS_516753] (unconjugated) bilirubin has been reported in the Phase 1/2 CCL [ZIP_CODE] study .
The potential of MMB to inhibit major drug transporters was studied in cells in which the 
individual transporters were over expressed and determining were possible the MMB IC 50 for the 
transport of probe substrates. MMB did not significantly inhibit P -gp, OAT1, OAT3, OCT1, 
OCT2, OATP1B1, OATP1B3 or BSEP mediated transport of probe substrates at 15 μM. MMB 
was determined to be an inhibitor of BCRP with an I C50 of 2.9 μM.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516754] characterized the safet y of MMB 
and included both repeat dose toxicology  studies and in vitro genotoxicity  studies. All pi[INVESTIGATOR_409737], including the genotoxicity  studies, were conducted in full compliance with 
good laboratory  practice ( GLP)regulations (21 CFR 58). The scope of the nonclinical safet y 
evaluation is consistent with guidance issued b y the International Conferen ce on Harmonisation 
(ICH).
The potential for MMB to induce hemod ynamic or electrocardiogram ( ECG ) effects was 
evaluated in male beagle dogs following a single oral dose of 5, 30 or 100 mg/kg. A marked 
decrease in mean arterial pressure and increase in hear t rate was observed after a single dose of 
100 mg/kg.
MMB was generally  well- tolerated clinically  when given to rats for 26 weeks at doses of 5 and 
15 mg/kg/day . There were three unscheduled deaths in the 50 mg/kg/day  group potentially  
related to MMB admin istration. By  [CONTACT_10585] 26, 50 mg/kg/day  group mean body  weight in males 
was 23.6% lower than control and in females was 13.1% lower than control. A reversible, mild 
slowing of caudal and digital nerve conduction velocity , consistent with a mild, minimally  
progressive and reversible deficit in distal sensory velocities, was observed at 50 mg/kg/day . At 
all dose levels, decreases in leukocy tes, ly mphocytes, eosinophils, and/or basophils were 
indicative of bone marrow and ly mphoid suppression (in spleen, ly mph nod e, thy mus, and/or gut 
associated l ymphoid tissue [ GAL T]). The m yelosuppres sion was considered adverse at 
50mg/kg/day . No histopathological correlate was observed. At 50 mg/kg/day , mild, reversible 
decreases in red cell mass (ery throcy tes, hemoglobin, and hematocrit) in both sexes, with 
concurrent increases in reticulocy tes and mean cell volume ( MCV )indicating an appropriate 
regenerative response, were observed. These alterations were associated with reversible increases 
in total bilirubin and correlated microscopi[INVESTIGATOR_409738] y in the kidney, mesenteric lymph nodes, liver, and spleen, and with 
erythrocy tosis/ery throphagocy tosis in the mandibular and mesenteric l ymph nodes. Dose related 
adverse findings due to GS -0387 administration included reversible minimal tubular 
degeneration/regeneration in the kidney  at≥ 15 mg/ kg/day  and mild decreased cellularit y in bone 
marrow, and irreversible degeneration/atroph y in testes and oligospermia/germ cell debris in 
epi[INVESTIGATOR_409739] 50 mg/kg/day . Due to the adverse changes in the kidney s at 15 mg/kg/day , the 
no observed adverse effe ct level was 5 mg/kg/day. Following 26 weeks at 5 mg/kg/day  in male 
and female rats, the GS -0387 AUC (0-24)values were [ZIP_CODE] and [ZIP_CODE] ng*hr/mL , respectivel y, 
and the C maxvalues were 4020 and 7590 ng/mL, respectively .
Momelotinib was well- tolerated when g iven orally to dogs once daily  for39 weeks at doses up to 
20 mg/kg/day . The majority  of dogs at 50 mg/kg/day  had periodic body  weight loss, decreased 
food consumption, and/or excessive emesis/vomitus, and three males at this dose were given 
week -long dose holiday s. One male at 50 mg/kg/day  was euthanized in extremis on Day  175 
with findings suggesting inanition play ed a role in the moribundity . Cataracts were observed in 
dogs at 50 mg/kg/day  at termination and persisted through the recovery  period. MMB -related 
microscopic findings were limited to the 50 mg/kg/day group and included minimal or mild 
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 20 18May 2015tubular epi[INVESTIGATOR_409740] s in both sexes and a minimal decrease in 
cellularity  in the bone marrow, mild spermatid/spermatocy te degeneratio n in the testes, and a 
mild increase in germ cell debris in the epi[INVESTIGATOR_409741]. The no -observed adverse effect 
level was considered to be 20 mg/kg/day . Following 39 weeks at this dose, the GS -0387 
AUC (0-24)value was 4620 ng*hr/mL, and the C maxvalue was 938 ng/mL.
The plasma AUC τin patients from Study  CCL [ZIP_CODE] at 300 mg capsule was 4.3 μg•h/mL . 
Therefore, the margin of exposure for the no-observed-adverse- effect -level ( NOAEL ) in the 
90-day toxicity  studies to the steady  state AUC NOAEL is 22 in the rat and 0.8 in the dogs.
An in vitro bacterial reverse mutation assay  (Ames test), an in vitro mammalian cell gene 
mutation assay  (chromosomal aberration test), and an in vivo rat bone marrow micronucleus 
assay  were conducted with MMB. No evidence of muta genicity  or clastogenicity  was observed 
indicating a low potential for MMB to cause genotoxicity . 
MMB was administered to adult male rats at 5, 25, and 100/68 mg/kg/day  for 4 weeks prior to 
mating and throughout mating (~10 weeks total). Mortality , adverse clinical signs, reduced bod y 
weight gain, reduced fecundity  and fertility , reduced testis and seminal vesicle weights and 
reduced sperm concentration and motility  occurred in the group administered 100/68 mg/kg/day . 
Reduced bod y weight gain, reduce d seminal vesicle weight and reduced sperm concentration and 
motility  occurred in the group administered 25 mg/kg/day . Reduced body  weight gain occurred 
in the group administered 5 mg/kg/day . The NOAEL  for male fertility  was 5 mg/kg/day . MMB 
was administer ed to adult female rats at 5, 25 or 100 (reduced to 68) mg/kg/day  for 14 day s prior 
to mating, throughout mating and through gestation day  (GD) 7.  Maternal toxicity  occurred after 
oral administration of 100/68 mg/kg/day  to adult female rats as evidenced b y mortalit y and 
associated clinical signs, reduced mean bod y weight and food consumption, significantl y 
reduced numbers of corpora lutea and mean number of estrous cy cles, and reduced mean ovarian 
and vagina weight. Adverse effects on cesarean section para meters were observed at 25 and 
100/68 mg/kg/day  and included an increase in early  resorptions, increased post -implantation loss 
and decreased number of live fetuses. Therefore, the no
-observed- effect level (NOEL) for 
maternal toxicity  and fertility  was 25 
mg/kg/day  and the NOEL for early  embry onic 
development was 5 mg/kg/day .
MMB when administered orally  to pregnant rats during organogenesis (from GD 6 -17) showed 
evidence of embry o-fetal toxicity . Adverse fetal effects were o bserved at 12 mg/kg/day . The 
12mg/kg/day  group had increased early  resorptions, percent post implantation loss, and reduced 
gravid uterus weight. The number of live fetuses and adjusted mean fetal weight were also 
reduced. Therefore, the NOAEL for maternal toxicity  was 12 mg/kg/ day  (GD 17 GS -
0387 C max
and AUC 0-tof 7.45 μg/mL and 75.8 μg•hr/mL, respectivel y). The NOAEL for embryo -fetal 
effects was 6 mg/kg/day  (GD 17 GS-0387 C maxand AUC 0-t of 3.58 μg/mL  and 25.5 μg•hr/mL, 
respectivel y).
MMB produced maternal toxicity  at 60 mg/kg/day whe n administered b y oral gavage to rabbits 
from GD 7 -20. Maternal toxicity  was based on reductions in food consumption as well as 
associated clinical signs. Embry o-fetal effects (reduced adjusted mean fetal weight, delay ed bone 
ossification, and an abortion) were considered secondary  to ma ternal toxicity  and not 
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 21 18May 2015GS-0387-01- related. Therefore, the NOAEL for maternal toxicity  was 30 mg/kg/day  which 
corresponded to GD 20 C max and AUC 0
-t values of 312 ng/mL and 543 ng•hr/mL  and the NOAEL 
for embry o-fetal toxicity was 60 mg/kg/day  which corresponded to GD 20 C maxand AUC 0 -t
values of 994 ng/mL  and 4100 ng•hr/mL, respectively .
A more detailed summary of findings from the studies in rats and dogs is available in the 
investigator brochure IB)for MMB. Investigators sh ould refer to this document prior to initiating 
therap y with MMB.
1.2.3. Clinical Trials of Momelotinib
Completed and Ongoing Clinical Trials
Please refer to the MMB IB for a listing of completed and ongoing MMB clinical trials.
1.2.4. Special Risk
Clinical development of the JAK2 inhibitor fedratinib (SAR302503) in myelofibrosis ( MF)was 
halted due to reported cases of Wernicke’s encephalopathy .  One case of suspected Wernicke’s 
encephalopath y has been reported with MMB.  Preliminary  nonclinical dat a have suggested that 
some JAK inhibitors, eg, fedratinib and AZD -1480, have the poten tial to inhibit the 
transporter -mediated uptake of thiamine from the intestine while others, including MMB, show 
no effect (data on file).  In order to understand the thi amine status of subjects with MF , thiamine 
level will be collected from all subjects at regular intervals across all MMB studies, with 
supplementation of thiamine as clinicall y indicated in the medical judgment of the treating 
physician.
1.3. Rationale for This Study
Targeted inhibitors of JAK2 including MMB and ruxolitinib have demonstrated significant 
clinical activity  in MF. Both drugs have been shown to provide substantial improvement in 
symptomatic splenomegaly  and constitutional sy mptoms. Ruxolitinib treat ment does not 
typi[INVESTIGATOR_1306] y lead to improvement in anemia, while patients on MMB were noted to experience 
improvement in anemia per International Working Group- Myelofibrosis Research and Treatment 
(IWG-MRT) criteria.  A mechanistic explanation for this differe ntial anemia response has not 
been elucidated. A phase 3 study  comparing the efficacy  of MMB versus ruxolitinib is currently  
ongoing, but specific biomarker studies to explore predictors and mechanisms of response were 
not able to be feasibly  incorporated in the study  design.
Anemia is a well -established prognostic factor in MF: 38% of patients have a Hgb level of 
<10g/dL and 24% required 
RBC transfusions at initial diagnosis { [ZIP_CODE]} . Additionally , the 
prevalence of anemia increases during the course of the disease. Ery thropoietin, the hormone that 
regulates RBCproduction, signals through JAK2 . Therefore , a JAK2 inhi bitor should reduce 
erythropoiesis , and aggravated anemia was not unexpected for ruxolitinib. Patients treated with 
MMB , however, experienced an improvement in anemia, with 53% of patients having a positive 
anemia response. To investigate the mechanism of this anemia benefit, markers of iron 
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 22 18May 2015metabolism will be evaluated in this study . Red blood cell transfusions, required by  [CONTACT_409755], relieve anemia sy mptoms, but exacerbate iron stor age. Markers of iron storage 
(eg,ferritin ), markers of available iron ( eg,serum iron and transferrin saturation) ,Liver Iron 
Concentration MRI  (LIC MRI ), and markers of ery thropoiesis will be ev aluated throughout this 
study , along with standard markers of inflammation. Furthermore, levels of the hormone 
hepcidin will also be tested. Hepcidin is considered to be the master regulator of iron 
homeostasis in the body , and responds to iron availabilit y, inflammatory  signals and other inputs 
{[ZIP_CODE]} .Increased hepcidin is associated with reduced dietary  iron absorption and reduced iron 
availability ,and is a poor prognostic factor for MF {[ZIP_CODE]} .  It is expected that markers of iron 
metabolism will help elucidate the MMB mechanism of anemia benefit as patients traverse from 
requiring transfusion to becoming transfusion -independent. 
Several important issues regarding the use of MMB in MF remain unresolved. Momelotinib, like 
ruxolitinib, inhibits both JAK1 and JAK2, and thus the relative role of JAK1 versus JAK2 
inhibition in providing clinical benefit in MF is uncertain. Anti -inflammatory  effects mediated 
by [CONTACT_166527]1 inhibition may  be critical. Furthermore, the degree to which MMB is able to “hit the 
target” in the cells that matter, the CD34+hematopoietic stem/progenitor cells (HSPC) that are 
thought to initiate and drive the disease, remains uncertain. Though several investigators have 
examined the effects of ex vivo treatment of primary  patient cells with JAK inhibitors, to date 
there have been no comprehensive studies examining the in vivo effects of JAK inhibitors on 
signaling in the HSPC compartment. This is largely related to the technical nuances of 
examining signaling in relatively  rare cells (HSPC) within complex, heterogeneous mixtures of 
cells, eg, blood or bone marrow. Conventional biochemical techniques are inadequate to address 
this important question.
Mass cy tometry  is a novel technology  that merges aspects of flow cy tometry  with mass 
spectrometry , thereby  [CONTACT_409756] > 30 parameters at the single 
cell level {[ZIP_CODE]} . Using such an approach, up to 15-[ADDRESS_516755] cell subsets across the entire hemat opoietic continuum, including HSPC as well as 
myeloid and l ymphoid lineage subsets. This technology  has been implemented in several recent 
studies { [ZIP_CODE]} { [ZIP_CODE] } {[ZIP_CODE]} { [ZIP_CODE] } {[ZIP_CODE]} .
In addition to query ing the effect of MMB on signaling in CD34+cells, this technique will also 
allow investigation of how signaling in this and other blood cell subsets changes in response to 
MMB treatment. Integrating mass cy tometry  data with expression profiling of blood cells before 
and during MMB treatment will enable better understanding of the biological basis of response 
to MMB.
1.4. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 23 18May [ZIP_CODE]. OBJECTIVES
The primary  objective of this study  is:
To determine the transfusion independence response rate for transfusion dependent  MF 
subjects treated with MMB
The secondary  objectives of this study  are:
To evaluate baseline levels and changes in markers of iron metabolism in transfusion 
dependent MF subjects treated with MMB
To assess inhibition of JAK1/2 in transfusion dependent MF subjects treated with MMB 
To evaluate MMB PK in transfusion dependent MF subjects
To evaluate changes in circulating cy tokine and inflammatory  markers in transfusion 
dependent MF subjects treated with MMB   
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516756] -PV/ET MF who are 
transfusion depend ent.  Subjects will receive MMB for 24 weeks (7 day s) on study .
After completion of the 24 week ( 7 day s) treatment phase visit procedures , subjects who 
respond to treatment, at the investigator’s discretion, will have the option of maintenance therap y 
with MMB on Study  GS-US-352- 1154 at the MMB dose they  tolerated and/or derived clinical 
benefit from during the 24 -
week treatment period. 
3.3. Study Treatments
The study  drug in is MMB, sup plied by  [CONTACT_10866]. The formulation and packaging of MMB are 
further described in Section 5.
3.4. Duration of Treatment
The duration of stud y treatment is 2 4 weeks (
±7 day s). Subjects will continue study  treatment 
until disease progression, unacceptable toxicity , consent withdrawal, or subject’s refusal of 
treatment.
3.5. Discontinuation Criteria
The study  may  be discontinued at any  time based on periodic reviews of safety  and efficacy  data 
by [CONTACT_10866].
Subject discontinuation criteria are described in Section 6.8.
3.6. Source Data
Patient reported outcomes data that are collected on paper will be considered source data.
Subject identification number captured b y the inte ractive web response s ystem (I WRS) is
considered source data. 
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 25 18May [ZIP_CODE].7. Biomarker Testing
3.7.1. Biomarker Samples to Address the Study Objectives:
The following biological specimens will be collected in this study  and used to evaluate the 
association of exploratory  systemic and/or tissue specific biomarkers with MMB response 
including efficacy  and/or adverse events, to increase knowledge and understa nding of the 
biology  ofMFandrelated diseases ,and may support development of possible companion
diagnostics. The specific anal yses will include, but will not be limited to, the biomarkers and 
assay s listed in Table 3-1.
Because biomarker science is a rapi[INVESTIGATOR_204935] , it is not possible to specify  
prospectivel y all tests that will be d one on the specimens provided. The testing outlined below is 
based upon the current state of scientific knowledge. It may  be modified during or after the end 
of the study  to remove tests no longer indicated and/or to add new tests based upon the growing 
state of 
our knowledge. Specimens will be collected from all subjects . 
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516757]
Blood
To evaluate the mechanism of anemia response of 
MMB, the tests to be performed may include but are not 
limited to:Iron studies, eg,serum iron level, total iron binding 
capacity, ferritin , non -transferrin bound iron, transferrin 
saturation, soluble transferrin receptor
Hepcidin, a peptide hormone that regulates iron 
metabolism and which demonstrates daily fluctuations 
in levels.  Testing for hepcidin requires strict adherence 
to time- of-day requi rements as described in 
Section 5.3.1
Com plete blood count, reticulocyte count
To evaluate pharmacodynamics response to MMB, the 
tests to be performed may include but are not limited to:Flow  cytom etric analysis of phosphorylated STAT3
Exploratory  pharmacodynamic stest
To evaluate the effect of MMB on inflammation, the 
tests to be performed include but are not limited to:Circulating cytokines and inflammatory markers ( eg,
interleukin -8 [IL -8], interleukin -2 receptor [ IL-2R[, 
interleukin 6 [IL -6], interferon gamma [IFN -], etc)
To evaluate how  MMB treatment influences survival 
and proliferative signaling in blood cells, including 
CD34+cells,  tests may include, but are not limited to:Mass cytometry to interrogate multiple signaling 
pathways, such as nuclear factor kappa- light-chain -
enhancer of activated B cells (NF -B) and RAS/MAP K 
Standard flow cytometry immunophenotypi[INVESTIGATOR_007], to 
investigate how  MMB treatment influences the relative 
percentages of the blood cell subsets 
Evaluation of gene expression patterns (RNA) and DNA 
mutations may be performed. 
To evaluate mutation status (eg,JAK2V617F, CALR), 
and whether allele burden changes with MMB 
treatment. Tests may include, but are not limited to:Molecular determination of JAK2V617F mutation
Molecular determination of other mutations that may be 
associated with MF ( eg,CALR, MPL, TET2).
Bone Marrow Biopsy
To evaluate fibrosis, RBC development, markers of 
MMB mechanism and stored iron, and whether MMB 
treatment influences these, the tests may include, but are 
not limited to:Trichrome, silver, Prussion blue, glycophorin, CD71 
stains
Evaluation of gene expression patterns (RNA) and DNA 
mutations may be performed
Liver Iron Concentration MRI
To evaluate iron storage in the liver (performed in conjunction with spleen MRI)
Buccal Swab
To provide normal genomic baseline for molecular studies .
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516758]'s death or loss of 
competence, the subject's specimens and data will continue to be used as part of the future 
research.
The s pecimens collected for future research, including bod y fluids, solid tissues, and derivatives 
thereof (eg, RNA, proteins, peptides), will be destroy ed no later than [ADDRESS_516759] 
(IRB
)-approved Informed Consent Form and applicable laws (eg, health authority  requirements).
3.7.3. Biomarker Samples for Genomic Research
The genomic sample (buccal swab) will be used to provide a normal baseline for each subject. 
This is required to correctly  identify  and validate disease -related somatic mutations in the 
planned molecular studies. 
In addition to the study -specific Informed Consent Form to be signed by [CONTACT_409757] y, a separate specific signatu re will be required to document a subject’s 
agreement to participate in genomic research.  The investigator or authorized designee will 
explain to each patient the objectives, methods, and potential hazards of participation in the 
genomic research. Subject s who decline to participate will not participate in the study . Subjects 
have the right to withdraw their consent for genomic research and stud y participation at an y time 
and for an y reason.  If a patient wishes to withdraw consent, the investigator must i nform the 
Sponsor.
In the event of a subject's death or loss of competence, the subject's specimens and data will 
continue to be used as part of the genomic testing.
The specimens consented for genomic research, including bod y fluids, solid tissues, and 
derivatives thereof (eg, DNA, proteins, peptides), will be destroy ed no later than 15 y ears after 
the end of the stud y.   The specimen storage period will be in accordance with the I RB-approved 
Informed Consent Form and applicable laws (eg, health authority requirements).
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516760] meet all of the following inclusion criteria to be eligible for participation in this 
study.
1)Age ≥ 18 y ears old
2)Diagnosis of PMF or Post PV/ET -MF
3)Requires my elofibrosis therapy , in the opi[INVESTIGATOR_871]
4)High risk OR intermediate -2 risk defined by [CONTACT_409758] s ystem 
(DIPSS)ORintermediate -1 risk defined b y DIPSS and associated with s ymptomatic 
splenomegaly  and/or hepatomegal y
5) Transfusion dependent at baselin e, defined as ≥ 4U RBC transfusion in the [ADDRESS_516761] dose of MMB
6) A cceptable organ function as evidenced by  [CONTACT_716]:
a)Platelet Count ≥ 50 x 109/L 
b) Aspartate aminotransferase ( AST/SGOT )and alanine aminotransferase ( ALT/SGPT )
≤ 3x upper limit of normal ( ULN )or  AST or ALT ≤ [ADDRESS_516762] if liver is involved by  
[CONTACT_409749] 
c)Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60mL/min
d)Direct bilirubin ≤ 2.[ADDRESS_516763]
7)Peripheral blood blast count < 20% 
8)Life expectancy  of > 24 weeks
9)
A negative serum pregnancy  test for female subjects (unless surgicall y sterile or greater than 
two y ears postmenopa usal) 
10)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 3
11)Lactating females must agree to discontinue nursing before MMB administration
12)Able to understand and willing to sign the informed consent form
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 29 18May [ZIP_CODE].3. Exclusion Criteria
Subjects who meet any of the following exclusi on criteria are not to be enrolled in this study .
1)Prior splenectomy
2) S plenic irradiation within 3months prior to the first dose of MMB
3)Prior treatment with MMB
4) Known positive status of human immunodeficiency virus ( HIV)
5)Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B 
and C), or hepatitis B or C carrier
6)Use of strong CYP3A4 inducer within [ADDRESS_516764] dose of MMB
7)
Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection,  
uncontrolled cardiac arrhythmia, or ps ychiatric illness/social situation that would limit 
compliance with study  requirements as judged by  [CONTACT_409759]
8)History  of a prior diagnosis of any  malignancy  other than PMF or Post PV/ET -MF except f or 
the following: adequatel y treated local basal cell or squamous cell carcinoma of the skin, 
cervical carcinoma in situ, superficial bladder cancer, as ymptomatic prostate cancer without 
known metastatic disease and with no requirement for therap y or requi ring only  hormonal 
therap y and with normal prostate specific antigen for >1 year prior to randomization, or any  
other cancer that has been in complete remission without treatment for ≥5 years prior to 
randomization
9)Treatment with a JAK inhibitor within [ADDRESS_516765] dose of MMB
10)Documented m yocardial infarction or unstable/uncontrolled cardiac disease ( eg, unstable 
angina, congestive heart failure [[LOCATION_001] Heart Association > Class III]) within 6 months 
of randomization
11)Presence of peripher al neuropathy  ≥ CTCAE Grade 2
12)Unwilling or unable to undergo a MRI per requirements in Section 
[IP_ADDRESS]
13)Unwilling to consent to genomics sampling
14)Pregnant or breast -feeding
15)Known hy persensitivity  to the study  investigational medicinal products, the metabolites, or 
formulation excipi[INVESTIGATOR_409734] (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 30 18May [ZIP_CODE]. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Enrollment and Treatment Assignment
Subjects will be enrolled via I WRS. All subjects will receive a starting dose of MMB 200 mg in 
a single tablet, taken orally  once -daily.
5.2. Descripti on and Handling of MMB
5.2.1. Formulation
MMB is supplied as GS -0387- 01(dihy drochloride monoh ydrate) and is available as 100 mg, 
150
mg, and 200 mg strength (as free base equivalent) tablets. The tablets contain excipi[INVESTIGATOR_840], 
microcry stalline cellulose, lactose monohy drate, sodium starch gl ycolate, silicon dioxide, 
magnesium stearate, propy l gallate, pol yvinyl alcohol, poly ethylene gl ycol, talc, titanium 
dioxide, y ellow iron oxide and red iron oxide. MMB tablets, 100 mg, are round -shaped , 
film-coated, brown table ts. MMB tablets, 150 mg, are round or triangle -shaped, film -coated, 
brown tablets. MMB tablets 200 mg, are capsule- shaped, film -coated, brown tablets.
5.2.2. Packaging and Labeling
MMB tablets are packaged in white, high -density  poly ethylene (HDPE) bottles. Each bottle 
contains 30 tablets, a silica gel desiccant, and polyester packing material. Each bottle is enclosed 
with a white, continuous thread, child resistant screw cap with an induction -sealed, aluminum 
faced liner. 
All MMB 
bottles will be labeled to meet all applicable requirements of the US Food and Drug 
Administration (FDA) and/or other local regulations as applicable.
5.2.3. Storage and Handling
MMB should be stored at controlled room temperature of 25ºC (77ºF); excursions are permitted 
between 15ºC and 30ºC ( 59ºF and 86ºF). 
Until dispensed to the subjects, all MMB bottles should be stored in a securely locked area, 
accessible only  to authorized site personnel. To ensure the stability  and proper identification, the 
drug products should notbe stored in a conta iner other than the container in which they  were 
supplied.
5.3. Dosage and Administration of MMB
5.3.1. Starting Dose
The starting dose of MMB for all subjects will be [ADDRESS_516766] MMB dose.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516767] occur betwe en 8 am and 10 am to accommodate the 
diurnal variation of hepcidin level.
5.3.2. Discontinuing or Interrupting MMB Treatment
When discontinuing treatment with MMB, dosing of MMB may  be tapered at the 
investigator’s 
discretion. For subjects on the [ADDRESS_516768] be ≥ 50 x 109/L prior to restarting treatment, regardless of the reason 
for treatment interruption. If toxicity  persists bey ond 28 day s, treatment may  be restarted upon 
sponsor approval.
5.3.4. Dose Adjustments for Thrombocytopenia
Platelet counts will be monitored throughout the study  and the dose of MMB adjusted based on 
the degree of thrombocy topenia as per Table 5-1.  
Table 5-1. MMB Dose Reductions for Subjects with Thrombocytopenia
Dose prior to reduction 200 m g QD 150 m g QD 100 m g QD
Platelet count Reduce to the dosebelow
50x 109/L No dose adjustment required
25x 109/L to<50x 109/L
If platelet cou nt 100 x 109/Lat study entry150 mg QD 100 mg QD Interrupt treatment
25x 109/L to<50x 109/L
If platelet count < 100 x109/Lat study entryNo dose adjustment required
<25x 109/L Interrupt treatment
After dose interruption for thrombocy topenia, treatment may  be restarted as per Table 5-2if 
platelet count is ≥ 50 x 109/L in the absence of platelet transfusion for at least 5 day s.  
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 32 18May 2015Table 5-2. Doses for Restarting MMB after Withholding Treatment for Toxicity
Dose at tim e of toxicity Restarting dose level
200 mg QD 150 mg QD
150 mg QD 100 mg QD
100 mg QD 100 mg QD
5.3.5. Dose Adjustments for Neutropenia
If the absolute neutrophil count ( ANC )is < 0.5 x 109/L, treatment will be interrupted. After 
recovery  of the ANC to ≥ 0.75 x 109/L, MMB may  be restarted per Table 5-2.
5.3.6. Dose Adjustments for Non -hematologic Toxicities
In the event of a new or recurrent Grade 3 or 4 non
-hematologic toxicity  that the investigator 
considers related to MMB, dosing will be interrupted for a maximum of 28 day s, inclusive of 
taper, until the toxicity resolve sor returns to baseline.  Upon resolution of the new or recurrent 
Grade 3 or 4 non -hematologic toxicity  MMB treatment may  be restarted as per Table 5-2.  If the 
toxicity  persists bey ond 28 day s, treatment may  be restarted only upon sponsor approval.
Ifa Grade 3 or 4 non- hematologic toxicity that the investigator considers related to MMB and 
had led to treatment interruption at the 100 mg once
-daily dose recurs after restarting MMB at 
100mg once -daily, treatment will be permanently discontinued.
5.3.7. Dose Adjustments Based on Response
If efficacy  is insufficient, subjects may  increase the dose of MMB after dose reduction, provided 
there is no new or r ecurrent :
Grade 3 or 4 non -hematologic toxicity  related to MMB , and/or
P
latelet count < 50 x 109/L, and/or 
ANC < 0.75 x 109/L
The dose may  not be increased during the first 4 weeks of therapy  or within 4 weeks of a dose 
reduction. Where a dose increase is permitted, the dose may  not be increased more frequentl y 
than every  2 weeks. The MMB dose may  be increased by  50 mg per dose adjustment to a 
maximum of 200 mg per day .
Insufficient efficacy  is defined as:
Failure to achieve a reduction from pretreatment baseline in either palpable spleen length of 
≥ 50% or spleen volume of ≥ 35% as measured b y MRI
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 33 18May [ZIP_CODE].3.8. Dose Adjustments for Other Toxicities
In the event of a toxicity  not covered in Sections 5.3.4 , 5.3.5 or 5.3.6 that the investigator 
considers related to MMB, the investigator may  interrupt dosing at their discretion for a 
maximum of 28 day s.  Following interruption, treatment may  be restarte d at the same dose level.  
If the investigator believes a dose reduction is warranted, treatment may  be restarted at a reduced 
dose level per 
Table 5-2with sponsor approval.  If treatment interruption persists bey ond 
28days, treatment may  be restarted only upon sponsor approval.
5.4. Prior and Concomitant Medications
5.4.1.
Restricted Medications
Anti- hypertensive therapy  should not be taken on the day  of the firs t MMB dose until 4 hours 
after MMB administration
Strong CYP3A4 inducers (eg, carbamazepi[INVESTIGATOR_050], pheny toin, St. John’s Wort) may  decrease 
MMB exposure and should be excluded
Moderate inducers of CYP3A/2C8/2C19 may  decrease MMB exposure and alternative 
medicati ons should be considered if clinicall y appropriat e when co-administered with MMB
5.4.2. Proscribed Medications
The following medications are proscribed during the treatment phase:
Experimental therapy other than MMB administered in this trial
Myelofibrosis therap y other than MMB administered in this trial
5.4.3. Breast Cancer Resistance Protein (BCRP) Substrates
In vitro, MMB was determined to be an inhibitor of BCRP. Results from a clinical drug -drug 
interaction study  suggested that multiple doses of MMB at 200 mg incre ased the exposure 
(Cmaxand AUC) of rosuvastatin (a BCRP substrate) b y approximately 3 fold. Plasma exposures 
of BCRP substrates may  increase when administered with MMB. As such, when appropriate, 
dose modification or alternative medications as clinically  appropriate should be considered when 
co-administered with MMB.
5.4.4. Organic Anion -Transporting Polypeptide (OATP) Inhibitors
MMB was determined to be a substrate of OATP1B1 and OATP1B3. A single dose of rifampin 
(potent inhibitor of OATP1B1 and OATP1B3) increa sed MMB C maxby ~40% and AUC infby 
~56%. Care should be exercised when MMB is co -administered with OATP inhibitors.
Refer to theIBof MMB for more details.  Refer to prescribing information of co -administered 
drugs prior to administration.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 34 18May [ZIP_CODE].5. Accountability for MMB
The investigator is responsible for ensuring adequate accountability  of all used and unused 
MMB .  This includes acknowledgement of receipt of each shipment of MMB (quantit y and 
condition). All used and unused MMB dispensed to subjects must be ret urned to the site.
MMB accountability  records will be provided to each stud y site to:
Record the date received and quantity  of MMB bottles
Record the date, subject number, subject initials, the MMB kit number dispensed
Record the date, quantity of used and unused MMB returned, along with the initials of the 
person recording the information.
5.5.1. MMB Return or Disposal
The methods of MMB return and destruction are described in Section 9.1.7.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516769] research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
A subject will be considered enrolled once enrolled in IWRS. It is the responsibility  of the 
investigator to ensure that each subject is eligible for the study  before enrolling the subject .
Details regarding treatment assignment are in section 5.1.
6.2. Study Procedure Descriptions
The sections below describe the individual study  procedures outlined in subsequent sec tions and 
the schedule of assessments (Appendix 2).
6.2.1. Informed Consent
All subjects must personally  sign and date the IRB approved informed consent form before an y 
study  procedures are performed (Section 9.1.3). 
6.2.2. Medical History
A complete medical and surgical history  will be obtained prior to enrollment and recorded on the 
eCRF. The medical history  will include 3 months of transfusion history  (Section [IP_ADDRESS]) prior 
to screening, and JAK2V617F mutation status, if documented.
6.2.3. Medication History
A history  of medications taken within the [ADDRESS_516770] practice. Phy sical examination 
findings during the screening period will either be reported as medical history  or adverse events 
(AEs) based on the requirements in Section 7.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516771] practice.
6.2.7. Laboratory Assessments
All samples for laboratory  assessments will be sent to the central laboratory with the exception 
of urine pregnancy  tests which will be completed at the site, if applicable. Local laboratory  
complete blood count ( CBC) assessments may  be collected as required for dose adjustments 
throughout the stud y. Local laboratory  assessments resulting in a dose change will be reported on 
the eCRF.
The central laboratory  will be responsible for chemistry , CBC with differential, urina lysis, 
hepatitis serology , and serum pregnancy  testing per Table 6-1and storage or shippi[INVESTIGATOR_409742]. Other tests listed in Table 6-1will be performed b y [COMPANY_009] or a designated 
laboratory . Any samples collected per the Schedule of Assessments ( Appendix 2) may  be 
analyzed for an y tests necessary  to ensure subject safet y. Specific instructions for processing, 
labeling, and shippi[INVESTIGATOR_53390] a central laboratory manual. The date and 
time of sample collection will be reported.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516772] bilirubin
GGT 
Glucose 
Iron
Iron binding capacity
Ferritin
LDH
Lipase
Magnesium
Non-transferrin bound iron
Phosphorus
Potassium 
Sodium
Total bilirubin 
Total protein 
Transferrin saturation
Soluble transferrin receptor
Uric acidColor and appearance
Specific gravity
pH
Occult blood
Protein
Glucose
Bilirubin
Leuk ocyte esterase
Ketones
Nitrite
Urobilinogen
Microscopi[INVESTIGATOR_409743]
% Hgb- Retic ulocytes
Neutrophils
Bands/stabs
Eosinophils
Basophils
Lymphocytes
Monocytes
% blasts
Absolute neutrophil count
PT (INR)b
PTTbSerum beta hCG
Hepatitis B surface antigen 
Hepatitis B surface 
antibody
Hepatitis B core antibody 
Hepatitis C antibody
MMB PK
C-reactive protein
Erythropoieti n
Hepcidin
Thiam ine
Pharm acody namics and
exploratory biomarkers
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; GGT = gam maglutamyl 
transpeptidase; LDH = lactate dehydrogenase; PT (INR)= Prothrombin time; PTT= partial thromboplastin time; RBC = red 
blood cell; WBC = white blood cell
a If applicable
b Baseline and Week [ADDRESS_516773] samples including: blood, Liver Iron 
Concentration (LIC) MRI, bone marr ow biopsy ,and buccal swab as indicated below . Refer to 
sections 6.3-6.5and Appendix 2for details regarding the biomarker sampling schedules.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 38 18May [ZIP_CODE].2.8.1. Blood Samples for Biomarker Anal ysis
Blood samples will be collected and transferred t o the central laboratory for anal ysis as whole 
blood, serum or plasma. 
[IP_ADDRESS]. Liver Iron Concentration MRI (LIC MRI)
This anemia -related test will be performed in conjunction with spleen MRI  to determine the 
amount of iron stored in the liver.
MRI s will be performed at local imaging centers and sent to a central imaging laboratory  for 
assessment of liver iron concentration. The central imaging laboratory  will provide instructions 
for collection and transfer of the LIC MRI. Repeat MRI  scans may  be required if the original 
scan is not accepted b y the central imaging laboratory , which may  occur if the scan is of poor 
quality . Computed tomography  (CT)scansmay not be performed.
The central imaging laboratory  will assess liver iron concentration as described in the 
Independent Review Charter.
[IP_ADDRESS]. Bone marrow biops y
The b one marrow biops y, and if possible , bone marrow aspi[INVESTIGATOR_337], should be processed according 
to the laboratory  manual and shipped to the central lab embedded in paraffin blocks unless a 
block o
r unstained tissue slides are already  available within 90 day s of the Screening visit. 
Bone marrow samples may  also be assessed for cy togenetic abnormalities at Baseline
(notrequired if previously  completed within 90 day s of the Screening visit and the r equired data 
are available for reporting to the eCRF). Cy togenetic assessments may  be repeated for subjects 
with abnormalities at Baseline for assessment of cy togenetic response.
[IP_ADDRESS]. Buccal Swab
The buccal swab will be performed to provide a normal genome samp le as a baseline to enable 
identification of somatic molecul ar changes related to disease. The sample should be collected at 
the Baseline visit, but may  be collected at any  time during the study .
6.2.9. Pharmacokinetics
Pharmacokinetics blood samples will be coll ected predose and at 2, 4, and 6 hours postdose at 
specified visits as instructed in sections 6.3-6.5.  
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 39 18May [ZIP_CODE].2.10. Patient -reported Outcomes Assessments (PRO)
[IP_ADDRESS]. Modified My eloproliferative Neoplasm Sy mptom Assessment Form Total 
Symptom Score (MPNSAF TSS) version 2
The modified MPNSAF TSS version 2 is an 8 item questionnaire developed to assess symptom 
burden and quality of life in patients with MPN.  The tot al symptom score is assessed over time 
to evaluate changes in MP N-related sy mptoms.  The questionnaire is completed daily on an 
electronic diary (eDiar y) device.
[IP_ADDRESS]. Patient Global I mpression of Change (PGIC)
The PGI C is a single question to assess the patient ’s impression of change in my elofibrosis 
symptoms since the start of study treatment. The Patient Global I mpression of Change (PGIC) 
scale assessed patients’ perceptions of change in their my elofibrosis sy mptoms over time. The 
PGIC has been widel y used to evaluate a patient’s overall sense of whether a treatment has been 
beneficial. In this study , subjects complete the PGIC on paper at the Week 24 visit. 
6.2.11. Disease Assessments
[IP_ADDRESS]. Dynamic International Prognostic Scoring S ystem ( DIPSS)
TheDIPSS for my elofibrosis will be assessed at scr eening to determine a subject’s study  
eligibilit y. Th e DI PSS score is assessed using a combination of the subject’s age, constitutional
symptoms, and hematologic parameters. The D IPSS score corresponds to a risk group: low, 
intermediat e-1, intermediat e-2, or high {[ZIP_CODE]} ( Appendix 4).
[IP_ADDRESS]. Spleen 
MRI
MRIswill be performed at local im aging center sand sent to a central imaging laboratory for 
assessment of spleen volume. The central imaging laboratory will provide instructions for 
collection and transfer of the spleen MRI. The spleen MRI will be performed in conjunction with 
the LI C MRI. Repeat MRI  scans may be required if the original scan is not accepted by [CONTACT_409760] , which may occur if the scan is of poor quality. CT scans may not be 
performed .
The central imaging laboratory will assess spleen volume as described in the Independent 
Review Charte r
.
[IP_ADDRESS]. Transfusion Recording
Subjects will record transfusion events in a diary during the screening period and throughout the 
study . The diary  will include instructions for the transfusion clinic to provide the date, t ype (eg, 
whole blood, platelets, packed cells), and number of units of the transfusion. Transfusion events 
will be reported on the eCRF. The hemoglobin or platelet value at the time of the transfusion will 
be reported on the eCRF as an observational component of the study .
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516774] signs the informed consent form. 
Subjects will complete screen ing and baseline assessments within 28days after signing the 
informed consent form to determine eligibility  for participation in the study . Subjects who do not 
enroll within the 
28day window will be screen failed . The following assessments will be 
performed and documented at the screening visit ( -[ADDRESS_516775] dose of MMB) :
Informed 
consent
Medical history (includes prior 3 months of transfusion histor y)
Medication history
Physical examination
Myelofibrosis symptoms assessment
Vital signs
Disease Status
DIPS
S
Distribution of eDiary  with instructions for collection of daily  modified MPNSAF TSS. 
Subjects will be issued a hand -held device and will complete the MPNSAF TSS 
questionnaire each night during screening through to the Week 24 visit.
Laboratory  
assessments:
Chemistry
Complete blood count (CBC) with diffe rential , reticulocy te count (including 
hemoglobi n-containing reticulocy tes)
Viral hepatitis B and C testing
Serum pregnancy  test, if applicable
C
-Reactive Protein (CRP)
Urinal ysis
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 41 18May 2015Biomarker Sampling:
Iron studies
Cytokines /chemokines
CD34+cell count
Gene expression
Immunophenot ype (flow cytometry)
From the time of obtaining informed consent t hrough the first administration of MMB , all 
serious adverse events (SAEs), as well as an y non-serious AEs related to protocol- mandated 
procedures 
must be recorded on the AE eCRF. All other untoward medical occurrences observed 
during the screening period, including exacerbation or changes in medical history are to be 
captured on the medical history eCRF. See S ection 7for additional details.
Laboratory assessments may be repeated [ADDRESS_516776] screening attempt that fall within the specified timeframes (eg, bone marrow aspi[INVESTIGATOR_337]/biopsy  
within 90 day s ofscreening visit ) do not need to be repeated.
6.3.2. Baseline Assessments
The following baseline assessments will be completed within 7 days (±2 day s) prior to first dose
of MMB , except for the ophthalmic examination which may  be completed at any  time during the 
screening period prior to first dose of MMB .
Laboratory  assessments and biomarker samplings must be completed ≥ 7 day s after a RBC 
transfusion.
Physical exam
Myelofibrosis sy mptoms assessment
Vital signs
Transfusion recording
Ophthalmic examination
Laborator y assessments:
CBC with differential ,reticulocy te count (including hemoglobin -containing 
reticulocy tes)
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 42 18May 2015Thiamine status
Erythropoietin (EPO)
CRP
Urine pregnancy  test
Biomarker Sampling:
Iron Studies
Hepcidin (between 8-10 am,and 6 hours later)
Exploratory  signaling ( mass cy tometry )
JAK2V617F allele burden, 
and other mutation tests
Buccal swab
Bone marrow biops y and if possible aspi[INVESTIGATOR_337] (not required if previously  completed within 
90[+14] day s of the Screening visit, andformalin -fixed paraffin embedded [FFPE] block 
or tissue slides plus the data are availab le)
Spleen & LIC MRI (per Section 6.2.11)
AEs and concomitant medications
6.4. Enrollment
Enrollment may  be completed following confirmation of subject eligibility  and completion of the 
above screening and 
baseline procedures . The I WRS will assign medication at the time of 
enrollment . The site will train the subject on the dosing schedule for MMB at the time of 
dispensing. The first dose of MMB may occur within [ADDRESS_516777] dose of MMB :
Modified MPNSAF TSS (completed dail y)
Physical examination
Myelofibrosis symptoms assessment
Vital signs
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 43 18May 2015Transfusion recording
Biomarker s ampling :
Pharmacod ynamics (predose , 2, 4, 6 hours postdose )
Pharmcokinetics (predose , 2, 4, 6 hours postdose )
Exploratory  pharmacod ynamic ssample ( predose , 2 hours postdose )
Hepcidin (predose , 6 hours postdose ) 
Cytokines /chemokines (predose , 6 hours postdose )
CD34+cell 
count ( predose )
Gene expression (predose )
Immunophenot ype(predose )
AEs and concomitant medications
MMB dosing
6.5. Treatment Assessments
Each on -study  visit will be scheduled based on the date of enrollment in IWRS . Visits will 
follow the schedule of assessments in Appendix 2.
6.5.1. Week 2
The Week 2 visit may  be completed within a window of ±3 day s. The following procedures will 
be completed at the 
Week 2 visit, unless otherwise specified:
Modified MPNSAF TSS (completed dail y)
Physical examination
Myelofibrosis sy mptoms assessment
Transfusion recording
Laboratory  assessments (all predose ):
CBC with differential, reticulocy te count (including hemoglobin -containing 
reticulocy tes)
CRP
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 44 18May 2015Biomarker Sampling:
Hepcidin ( predose , 6 hrs postdose ) 
Iron Studies
AEs and concomitant medications
6.5.2. Week 4, 8, 12, 16 and Week 2 0
On-studyvisits during this period may be completed within a window of 3 day s. The following 
procedures will be completed at each visit, unless otherwise specified:
Modified MPNSAF TSS (completed dail y)
Physical examination
Myelofibrosis sy mptoms assessment
Vital signs
Transfusion recording
Laboratory  Assessments :
CBC with differential ,reticulocy te count (including hemoglobin -containing 
reticulocy tes)(All visits
, predose )
Chemistry  (Week 12 only , predose )
Thiamine status ( Week 12 only , predose )
Erythropoietin (
Weeks 8, 20, predose )
CRP (Week 12 only, predose)
Urinaly sis
Biomarker Sampling :
Hepcidin ( All visits, predose , 6 hours postdose )
Iron Studies(all visits, 
predose )
Cytokines /chemokines (All visits, predose )
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 45 18May 2015CD34+cell count (Week 12, 20 predose )
Immunophenot ype (flow cytometry) (Week s12, 20 ,predose )
Gene expression (Weeks 12, 20, predose )
Exploratory  signaling (mass cy tometry ) (Weeks 4, 12 , predose )
Pharmacod ynamics (Week 4predose , 2, 4, 6 hour s postdose )
Pharmacokinetics (Week 4 predose , 2, 4, 6 hours postdose )
Urine pregnancy test 
(all visits ; if applicable)
AEs and concomitant medications
MMB accountability anddispensing
6.5.3. Week 24
Subjects will complete the Week 24 visit within a window of 7days. Subjects will continue 
MMB treatment until completion of this visit. The following procedures will be completed:
Modified MPNSAF TSS (completed dai ly;theeDiary will be collected at thisvisit)
PGIC Questionnaire
Physical examination
Myelofibrosis sy mptoms assessment
Vital signs
Transfusion recording
Laborator yassessments :
Chemistry (predose )
CBC with differential ,reticulocy te count (including hemoglobin -containing 
reticulocy tes)(predose )
Thiamine status (predose )
CRP (predose)
Urinaly sis
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 46 18May 2015Biomarker Sampling:
Hepcidin ( predose , 6 hours postdose )
Exploratory  signaling (mass cy tometry )
(predose )
Iron Studies ( predose )
Cytokines /chemokines (predose )
JAK2V617F allele burden, and other mutation tests
Pharmacod ynamics ( predose , 2, 4, 6 h ours postdose )
Pharmacokinetics ( predose , 2, 4, 6 hours postdose )
Bone marrow biops y/aspi[INVESTIGATOR_337]
Urine pregnancy  test (if applicable) 
Ophthalmic examinatio ns
Spleen & LIC MRI(per Section 6.2.11 )
AEs and 
concomitant medications
MMB accountability
6.6. Unscheduled visits
Unscheduled visits may  occur at any  time during the study . Vital signs, laboratory  assessments, 
physical examination and MMB dispensation may be conducted at these visits.
6.7. Post-treatment Assessments
6.7.1. E arly Study Drug Discontinuation
Subjects discontinuing study  MMB prior to the Week 24 visit will complete the Earl y Stud y 
Drug Discontinuation (ESDD) visit and will
not be eligible to receive MMB maintenance 
treatment . The following procedures will be completed within 7 d ays of early  MMB 
discontinuation :
Modif ied MPNSAF TSS (completed dail y, the eDiary  will be collected at this visit )
Physical examination
Myelofibrosis symp toms assessment
Vital signs
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 47 18May 2015Spleen and LIC MRI
Ophthalmic examinations (not required if completed within 12 weeks prior to ESDD)
Laboratory  assessments :
Chemistry
CBC with differential , reticulocy te count (including hemoglobin -containing 
reticulocy tes)
CR
P
Urinaly sis
Urine pregnancy  test (if applicable)
Biomarker Sampling:
JAK2V617F allele burden, and other mutation tests
Transfusion recording
AEs and concomitant medications
MMB accountability  (if required)
6.7.2. 30- Day Follow -up Assessments
The following procedures will be completed [ADDRESS_516778]’s last dose of MMB , within 
a window of ±7 day s. Subjects completing the Week 24 visit and entering maintenance treatment 
on study  GS-US-
352-1154 will not complete the 30 -Day Follow Up visit:
Physical examination
Myelofibrosis sy mptoms assessment
Vital signs
Laboratory  assessments :
Chemistry
CBC with differential ,reticulocy te coun t(including hemoglobin -containing 
reticulocy tes)
Urinaly sis
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 48 18May 2015Transfusion recording
AEs and concomitant medic ations
6.8. Criteria for Discontinuation of Study Treatment
Study  medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator.
Unacceptable toxicity , ortoxicity  that, in the judgment of the investigator, compromises the 
ability  to continue study -specific procedure s or is considered to not be in the subject ’
s best 
interest
Disease progression
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 3
Discontinuation of the study  at the request of [COMPANY_009] , aregulatory  agency  or an IRB
6.9. End of Study
End of Study  for a subject is defined as the date of the last study -related procedure or the date of 
death for an on-study  subject. All treatment -emergent AEs and laboratory  abnormalities present 
at the end of stud y are to be followed until resolution or the event is determined to be irreversible 
by [CONTACT_093].
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 49 18May [ZIP_CODE]. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which 
does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred ( eg,hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.7.1 )
Any medical con dition or clinically significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  case 
report form ( CRF )
.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the fol lowing :
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_409744] (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 50 18May 2015Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may  not be immediately  life-
threatening or result in death or hospi[INVESTIGATOR_122011]. Medical and scientific 
judgment 
must be exercised to determine whether such an event is areportable under 
expedited reporting rules. 
Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edicall y important e vent and subject to expedited reporting 
requirements.
[IP_ADDRESS]. Protocol -Specific Serious Adverse E vent Instructions
To maintain the integrit y of the study , the following events that are assessed as unrelated to 
MMB will not be considered as SAEs:
Progression of my elofibrosis
Death related to progression of my elofibrosis
However, events of progression o f myelofibrosis and death due to progression of my elofibrosis 
that are assessed b y the investigator to be related to MMB will be considered as SAE and will be 
reported to regulatory  agencies b y [COMPANY_009] accordingl y.
All events of progression of my elofibrosis and death related to progression of my elofibrosis, 
regardless of investigator assessment of relationship to MMB, will be reported in the eCRFs and, 
as appropriate, in the final clinical study  report (CSR) and in any  relevant aggregate safet y 
reports.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to MMB interruption, modifi cation, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.[ADDRESS_516779] the sy ndrome or diagnosis (eg, anemia), not the laboratory  result 
(eg, decreased hemoglobin).
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 51 18May 2015For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for MMB and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to 
MMB therap y using clinical judgmen t and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than MMB treatment . For 
SAEs, an alternative causality  must be provided (eg, pre -existing condition, underly ing 
disease, intercurrent illness, or concomita nt medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse eve nt reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures ( eg,venipun cture )
7.2.2. Assessment of Severity
The severit y of AEs will be graded using the Common Terminology  Criteria for Adverse Events 
(CTCAE ), Version 4.03. For each epi[INVESTIGATOR_1865], the highest severit y grade attained should be reported.
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: Grade 1 
(mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life -threatening), or Grade 5 (fatal) to 
describe the maxim um intensity  of the AE. For purposes of consistency  with the CTCAE, these 
intensity  grades are defined in Table 7-1.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516780]’s overall health and w ell-being, does 
not interfere with the subject’s usual function, and is not likely to require 
medical atten tion.
Grade [ADDRESS_516781] clinical status, 
and may require medical intervention.
Grade 3 SevereSign or symptom is incapacitating or significantly affects clinical status and 
likely requires medical intervention and/or close follow -up.
Grade 4 Life-threatening Sign or symptom results in a potential threat to life.
Grade 5 Fatal Sign or symptom results in death.
The distinction between the seriousness and the severity  of an AE should be noted. Severit y is a 
measure of intensit y; thus, a severe reaction is not necessarily  a serious reaction.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009] 
Requirements for collection pr ior to initiation of MMB :
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case re port form eCRF: all SAEs and adverse events related to 
protocol -mandated procedures.
7.3.1. Adverse Event s
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until [ADDRESS_516782] consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and [COMPANY_009] Drug Safety and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516783] dose of MMB , regardless of causalit y, should also be reported. 
Investigators are not obligated to activel y seek SAEs after 
the protocol defined follow up period. 
However, if the investigator learns of any  SAEs that occur after stud y participation has 
concluded and the event is deemed relevant to the use of MMB , he/she should promptly  
document and report the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in th e 
eCRF completion guideline.
[IP_ADDRESS]. Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of t he event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event r eporting 
form and submit within 24 hours as described above to [COMPANY_009] DSPH: email  
Safety [EMAIL_202]; or fax +1 (650) 522 -5477
.
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/ eCRF and the event description section of the SAE 
form.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 54 18May [ZIP_CODE].4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regu
lations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, [COMPANY_009] may  berequired to expedite to 
worldwide regulator y agencies reports of SAEs , serious adverse drug reactions (SADRs) ,or 
suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide regulator y 
agencies and the relevant IECin concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_10855] i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with MMB . The investigator should notify  the IRB of S[LOCATION_003]R reports as soon as is practical, 
where this is required b ylocal regulatory  agencies , and in accordance with the local institutional 
policy . 
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs or SAE s (Section 7.1.3). When 
laboratory  abnormalities are recorded as AEs or SAEs, severit y should be recorded and graded 
according to the CTCAE Version 4.03 except for anemia (hemoglobin, Hgb) which will be 
graded using the CTCAE Version 3.0 as defined in Table 7-2.
Table 7-2. Grading of Anemia (H gb) Severity
Grade (CTCAE 3.0)
1 2 3 4 5
<LLN –10.0 g/dL
<LLN –6.2 mmol/L
<LLN –100 g/L<10.0 –8.0 g/dL
<6.2 –4.9 mmol/L
<100 –80 g/L<8.0 –6.5 g/dL
<4.9 –4.0 mmol/L
<80 –65 g/L<6.5 g/dL
<4.0 mmol/L
<65 g/LDeath
7.6. Toxicity Management 
Dosing requirements for certain toxicities are specified in Section 5.3and 5.3.3. The investigator 
may contact [CONTACT_409761]. Laboratory  abnorm alitie s (eg, below normal thiamine level) identified at 
Screening/Baseline and during stud
y participation should be treated at the investigator’s 
discretion.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516784] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be estab lished only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
7.7.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post MMB treatment
follow -up period, to [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming 
aware of the pregnancy .
Refer to section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to termina te a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons
) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516785] information is as follows: 
Email: Safety [EMAIL_202] and Fax: +1 (650) [ADDRESS_516786] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the stud y 
has been completed, the outcome should be reported directl y to [COMPANY_009] DSPH, email 
Safety [EMAIL_202] or fax +1 (650) 522- 5477. 
Refer to Appendix 3for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_516787] of situations that involve MMB and/or [COMPANY_009] concomitant 
medications, but do not apply to non-[COMPANY_009] concomitant medications. 
Special situations involving non-[COMPANY_009] concomitant medications donot need to be reported on 
the special situati ons report form; however, for special situations that result in AEs due to a non-
[COMPANY_009] concomitant medication , the AE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 57 18May [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is:
To determine the transfusion independence response rate for transfusion dependent MF
subjects treated with MMB
8.1.2. Primary Endpoint
The primary  endpoint is :
Transfusion independence response rate b y Week 24, defined as becoming transfusion 
independent for ≥ [ADDRESS_516788] is considered as transfusion 
independent on study  if no RBC transfusion occurs in any  12 weeks during the 24- week 
treatment period.
8.1.3. Secon dary Endpoint s
Secondary  endpoints are :
Transfusion response rate by [CONTACT_10585] 24, defined as becoming not transfusion dependent 
for ≥ 8 weeks at an y time on study   
Baseline and change in marker of anemia (eg, hepcidin, ferritin)
Change in pharmacod ynamics biomarker pSTAT3
Splenic response rate at Week 24, defined as ≥ 35% reduction in spleen volume from 
baseline as measured b y MRI
Response rate in TSS at Week 2 4, defined as achieving a ≥ 50% reduction from baseline 
in TSS as measured b y the modified MPNSAF TSS diary
Pharmacokinetics parameters (C max, Clast, Ctauand AUC last, if available) for MMB 
Change in circulating cy tokine and inflammatory  markers (eg, IL -6, IL -8, IFN gamma, 
TNF alpha)
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 58 18May [ZIP_CODE].1.4. Exploratory Endpoint s
The exploratory  endpoints are:
Baseline and c hang e in markers of orthogonal or parallel signaling pathway s (eg,
RAS/MAPK, PI 3K/AKT)
Baseline and c hange in gene expression profiles in whole blood and change in somatic 
mutations in whole blood , if applicable.
Baseline and c hange in immune subsets in whole blood 
Change in exploratory  pharmacod ynamics markers of signaling mediated by [CONTACT_166527]1 and/or 
JAK2 (eg,pSTAT1, pSTAT5, and pSTAT6)
8.2. Analysis Conventions
8.2.1. Analysis Sets
[IP_ADDRESS]. Safety Anal ysis Set
The Safet y Analysis Set includes all subjects who receive ≥ [ADDRESS_516789]’s characteristics, efficacy  and 
safet y endpoints, and study treatment administration.
[IP_ADDRESS]. Biomarker Anal ysis Set
The Biomarker Anal ysis Set consists of all subjects in the Safety  Anal ysis Set who have the 
necessary  baseline and on
-study  measurements to provide interpretable results for the specific 
parameters of interest. The Biomarker Analy sis Set will be used for biomarkers and the 
correlation anal yses between biomarkers and efficacy clinical endpoints.
[IP_ADDRESS]. Pharmacokinetic s(PK) Analy sis Set
The PK Anal ysis Set consists of all subjects in the Safety  Anal ysis Set who have the necessary  
baseline and on -study  measurements to p rovide interpretable results for the specific parameters 
of interest.
8.3. Data Handling Conventions
By-subject listings will be created for important variables from each eCRF module. Summary  
tables for continuous variables will contain the following statistics : N (number in population), n 
(number with data), mean, standard deviation (StD), 90% confidence intervals (CI s) on the 
mean, median, minimum, and maximum. Summary  tables for categorical variables will include: 
N, n, percentage, and 90% CI s on the percenta ge. Unless otherwise indicated, 90% CIs for binary  
variables will be calculated using the binomial distribution (exact method) and will be 2 sided. 
Data will be described and summarized by  [CONTACT_409762], anal ysis set, and time point. As 
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516790] change from baseline during the 
study  will also be described and summarized by  [CONTACT_15994]. Graphical techniques (eg, wat erfall 
plots, Kaplan -Meier curves, line plots) may  be used when such methods are appropriate and 
informative.
The baseline value will be the last (most recent) pre- treatment value. Data from all sites will be 
pooled for all analy ses. Analy ses will be based upon the observed data unless methods for 
handling missing data are specified. If there is a significant degree of non -normality , analy ses 
may be performed on log- transformed data or nonparametric tests may  be applied, as 
appropriate. 
8.4. Demographic Data an d Baseline Characteristics
Subject demographic and baseline characteristics will be listed and summarized for the Safet y 
Analy sis Set. Imbalances in subject characteristics may  be compared using the Wilcoxon rank -
sum test for continuous variables and the F isher’s exact test for categorical variables.
8.5. Efficacy Analysis
Transfusion independence response rate, transfusion response rate, splenic response rate and 
response rate in TSS will be presented with corresponding 2 -sided 90% exact CI s using the 
binomial distribution. Subjects who do not have sufficient baseline or on -study  assessment to 
characterize the response will be counted as non -responders.
8.6. Safety Analysis
All safet y data collected on or after the date that MMB was first dispensed up to the date of last 
dose of MMB plus 30 days will be summarized. Data for the pretreatment will be included in 
data listings.
8.6.1. Extent of Exposure
Descriptive information will be provided by  [CONTACT_409763] t he number of doses of MMB
prescribed, the total number of d oses taken, the percent of expected doses taken, the number of 
days of MMB treatment , and the number and timing of prescribed dose modification and 
interruptions.
Compliance will be described by  [CONTACT_409764][INVESTIGATOR_409745] (taking into account 
physician -prescribed modification and interruptions).
8.6.2. Adverse Events
All AEs will be listed. The focus of AE summarization will be on treatment -emergent AEs. A 
treatment -
emergent AE is defined as an AE that occurs or worsens in the period from the first 
dose of MMB to [ADDRESS_516791] dose of MMB.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 60 18May 2015AEs will be coded us ing the Medical Dictionary  for Regulatory  Activities (MedDRA 
http://www.meddramsso.com) with descriptions by  [CONTACT_1196] (SOC), High Level 
Group Term, High- Level Term, Preferred Term, and L ower -Level Term.  The severit y of AEs 
will be graded b y the investigator according to the CTCAE, Version 4.03, whenever possible. If 
a CTCAE criterion does not exist for a specific type of AE, the grade corresponding to the 
appropriate adjective will be used b y the investigator to describe the maximum intensity  of the 
AE: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life threatening), or Grade 5 
(fatal). Th e relationship of the AE to MMB will be categorized as related or unrelated.
Treatment -emergent AEs will be summarized by  [CONTACT_15994]. Summary  tables will be presented to 
show the number of subjects reporting treatment -emergent AEs b y severity  grade and 
corresponding percentages. A subject who reports multiple treatment -emergent AEs within the 
same Preferred Term (or Sy stem Organ Class) is counted only once for that Preferred Term 
(orSystem Organ Class) using the worst severit y grade.  AE descriptions will be presented b y 
decreasing frequency  for a given Sy stem Organ Class and Preferred Term. Separate listings and 
summaries will be prepared for the following t ypes of treatment emergent AEs:
Study -drug-related AEs
AEs that are Grade ≥ 3 in severit y
AEs leading to 
MMB interruption and/or dose modification
AEs leading to MMB discontinuation
SAEs
8.6.3. Laboratory Evaluations
All laboratory  data will be listed. Summaries of laboratory  data will be based on observed data. 
The focus of laboratory  data summarization will be on treatment -emergent laboratory  
abnormalities. A treatment -emergent laboratory  abnormality  is defined as an abnormalit y that, 
compared to baseline, worsens b y >[ADDRESS_516792] dose of MMB . If baseline data are missing, then an y graded abnormality  (ie, an 
abnormality  that is Grade > 1 in severit y) will be considered treatment emergent.
Hematological, serum biochemistry , and urine data will be programmatically  graded according 
to CTCAE severity  grade, when applicable. For parameters for which a CTCAE scale does not 
exist, reference ranges from the central l aboratory will be used to determine programmatically  if 
a laboratory  parameter is below, within, or above the normal range for the subject’s age, sex, etc.
Hematological and serum biochemistry  and their changes from baseline will be summarized by  
[CONTACT_152867] l, by [CONTACT_765]. Summary  tables will be presented for each relevant assay  to show the 
number of subjects b y CTCAE severit y grade with corresponding percentages. For parameters 
for which a CTCAE scale does not exist, the frequency  of subjects with values below, within, 
and above the normal ranges will be summarized. Subjects will be characterized only  once for a 
given assay , based on their worst severit y grade observed during a period of interest (eg, during 
the study  or from baseline to a particular visit).
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516793] baseline. Separate listings and summaries will be prepared for 
laboratory  abnormalities that are Grade ≥ 3 in severity .
8.7. Pharmacokinetic sAnalysis
The concentration data of MMB and its major metabolite GS-644603 will be summarized by  
[CONTACT_10863]. PK parameters (C max, Clast, Ctau, and AUC last, 
if available), will be listed and summarized using descriptive statistics (eg, sample size, 
arithmetic mean, geometric mean, coefficient of variation (%) standard deviation, median, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi logarithmic 
and linear formats as mean ± standard deviation, and median (Q1, Q3) if applicable. Exposure -
response relati onship may  also be evaluated.
8.8. Biomarker Analysis
The baseline levels, and changes in biomarker levels over time from baseline level, will be 
evaluated. Descriptive statistics will be provided at each sampling time, and by  [CONTACT_409765] l endpoint being considered for association with biomarkers, as 
appropriate. Exploratory  graphics, such as side -by-side boxplots will also be generated.
Univariate and multivariate statistical techniques may  be explored to evaluate the association of 
basel ine biomarkers and changes in biomarkers with clinical outcomes as appropriate. Due to the 
exploratory  nature of the end points, no formal hypothesis testing will be conducted.
8.9. Sample Size
This st udy will enroll approximately [ADDRESS_516794] 
90% CI s using the binomial distribution for a given transfusion independence response rates 
ranging from 0.10 to 0.5. 
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516795] 90% CIs for various response rates
No. of Responders Response Rate Exact 90% CI (N=40)
4 0.10 (0.035, 0.214)
6 0.15 (0.067, 0.274)
8 0.20 (0.104, 0.332)
10 0.25 (0.142, 0.387)
12 0.3 (0.183, 0.440)
14 0.35 (0.226, 0.492)
16 0.4 (0.269, 0.542)
18 0.45 (0.315, 0.591)
20 0.5 (0.361, 0.639)
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 63 18May [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. 
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” [ADDRESS_516796] be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_516797] (IRB) Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB. The investigator will not begin an y stud y subject activities until 
approval has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRBany modifications made to the protocol or any  accompany ing material to be provided to 
the subject after initial IRBapproval, with the exception of those necessary to reduce immediate 
risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consen t from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y
-related procedures. The 
investigator must use the most current IRB approved consent form for documenting written 
informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion , and also by  [CONTACT_409766].
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516798] assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject i nitials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor ,or laboratory . Laboratory  specimens must 
be labeled in such a way  as to prote ct subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions . NOTE :The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations. 
The investigator agrees tha t all information received from [COMPANY_009], including but not limited to the 
investigator 
brochure, this protocol, eCRF , MMB , and any  other stud y information, remain the 
sole and exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. This
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precau tions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of th e stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s study  file will contain the protocol/amendments, CRF and query  forms, IRB
and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The re quired source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examinatio n, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all 
visits;
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 65 18May 2015Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of MMB , including dates of dispensing and 
return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_516799] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_516800] visit to enable the sponsor to perform central monitoring 
of safet y data.  Subsequent to data entry , a stud y monitor will perform source data verification 
within the electronic data capture (EDC )system. Original entries as well as any
 changes to data 
fields will be stored in the audit trail of the s ystem.  Prior to database lock (or any  interim time 
points as described in the clinical data management plan), the investigator will use his/he r log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  [CONTACT_110105], 
who routinely  review the data for completeness, correctness, and consistency . The site 
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516801] or updating the original entry, and providing the reason 
for the update ( eg,data entry  error). At the conclusion of the trial, [COMPANY_009] will provi de the site 
with a read -only archive copy  of the data entered by  [CONTACT_10867]. This archive must be stored in 
accordance with the records retention requirements outlined in Section
 9.1.[ADDRESS_516802] Accountability and Return
[COMPANY_009] recommends that used and unused MMB supplies be returned to the shippi[INVESTIGATOR_409746]. The study  monitor will provide instructions for 
return. If return is not possible, the study  monitor will evaluate each stud y center’s disposa l 
procedures and provide appropriate instruction for destruction of unused MMB supplies. If the 
site has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
[COMPANY_009] QA, the site may  destroy  used (empt y or partially empty) and unused MMB supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files. 
If MMB is destro yed on site, the investigator must maintain accurate records for all MMB
destroy ed. Records must sh ow the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the MMB supplies . Upon study  completion, 
copi[INVESTIGATOR_1093] a ccountability  records must be fil ed at the site. Another cop y will be returned to 
[COMPANY_009].
The study  monitor will review MMB supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y monitors , to IRBs, or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Proto col Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by [CONTACT_10866]. The investigator must submit a ll protocol modifications to the IRBin 
accordance with local requirements and receive doc umented IRB approval before modifications 
can be implemented.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 67 18May [ZIP_CODE].2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency (ies). [COMPANY_009] 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl ymedia only  after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed by [CONTACT_337370], manuscript, or presentation form, OR
The study  has been completed at all stud y sites for at least [ADDRESS_516803] 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obt
ain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e g,attendance at I nvestigator's Meetings.  If requ ired under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  ofthe data recorded in the 
eCRF .
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The m onitor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected 
through an y type of monitoring (eg, central, on site) are resolved.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516804] of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), and I RBs. In terminating the s tudy, [COMPANY_009] and the investigator will 
assure that adequate consideration is given to the protection of the subjects’ interests.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516805] C, Fourouclas N, Swanton S, et al. 
Acquired mutation of the ty rosine kinase JAK2 in human my eloproliferative 
disorders. Lancet 2005;365 (9464):1054 -61.
[ZIP_CODE] James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A 
unique clonal JAK2 mutation leading to constitutive signalling causes 
polycythaemia vera. Nature 2005;434 (7037):1144 -8.
[ZIP_CODE] Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain -
of-function mutation of JAK2 in my eloproliferative disorders. N Engl J Med 
2005;352 (17):1779-90.
[ZIP_CODE] Cervantes F, Dupriez B , Pereira A, Passamonti F, Reilly  JT, Morra E, et al. New 
prognostic scoring s ystem for primary  myelofibrosis based on a study of the 
International Working Group for M yelofibrosis Research and Treatment. Blood 
2009;113 (13):2895-901.
[ZIP_CODE] Hasselbalch HC. Perspectives on chronic inflammation in essential 
thrombocy themia, pol ycythemia vera, and my elofibrosis: is chronic inflammation 
a trigger and driver of clonal evolution and development of accelerated 
atherosclerosis and second cancer? Blood 2012;119 (14):3219-25.
[ZIP_CODE] Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization 
classification s ystem for my eloproliferative neoplasms: order out of chaos. Cancer 
2009;115 (17):3842
-7.
[ZIP_CODE] Quintas -Cardama A, Cortes J. Molecular biology  of bcr-abl1- positive chronic 
myeloid leukemia. Blood 2009;113 (8):1619-30.
[ADDRESS_516806] oS ONE 2013;8 (1):e54826.
[ADDRESS_516807] survival in primary  myelofibrosis: a study  
by [CONTACT_190949] -MRT (International Working Group for My eloproliferative 
Neoplasms Research and Treatment). Blood 2010;115 (9):1703
-8.
[ZIP_CODE] Abdel -Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, et al. Genetic 
analysis of transforming events that convert chronic myeloproliferative neoplasms 
to leukemias. Cancer Res 2010;70 (2):447 -52.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516808] upon the therapeutic landscape for m yelofibrosis: from palliation to cure? 
Br J Haematol 2012;157 (4):426 -37.
[ZIP_CODE] Patriar ca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, et al. 
Allogeneic hematopoietic stem cell transplantation in my elofibrosis: the 20- year 
experience of the Gruppo I taliano Trapi[INVESTIGATOR_186842] (GITMO). 
Haematologica 2008;93 (10):1514 -22.
[ZIP_CODE] Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. 
Somatic CAL R mutations in my eloproliferative neoplasms with nonmutated 
JAK2. N Engl J Med 2013;369 (25):2391
-405.
[ZIP_CODE] Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaid ya R, e t al. One 
thousand patients with primary  myelofibrosis: the mayo clinic experience. Mayo 
Clin Proc 2012;87 (1):25-33.
[ZIP_CODE] Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Bioph ys Acta 
2012;1823 (9):1434-43.
[ZIP_CODE] Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and 
prognostic interactions between circulating levels of hepcidin, ferritin and 
inflammatory  cytokines in primary  myelofibrosis. Am J Hematol 2013;88 
(4):312-6.
[ZIP_CODE] Bendall SC, Nolan GP. From single cells to deep p henoty pes in cancer. Nat 
Biotechnol 2012;30 (7):639-47.
[ZIP_CODE] Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single -
cell mass cy tometry  of differential immune and drug responses across a human 
hematopoietic continuum. Science 2011;3 32 (6030):687 -96.
[ZIP_CODE] Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, et al. 
Multiplexed mass cy tometry  profiling of cellular states perturbed by  [CONTACT_34677] -
molecule regulators. Nat Biotechnol 2012;30 (9):858-67.
[ZIP_CODE] Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. 
viSNE enables visualization of high dimensional single
-cell data and reveals 
phenoty pic heterogeneit y of leukemia. Nat Biotechnol 2013;31 (6):[ADDRESS_516809] CE, et al. 
Decoupling of tumor -initiating activity  from stable immunophenoty pe in HoxA9 -
Meis1 -driven AML. Cell stem cell 2012;10 (2):210-7.
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516810]. 
Single Cell Mass Cy tometry Reveals Hy peractivated Signaling Networks in 
Myeloproliferative Neoplasms [Abstract]. Blood 2014;124 (21).
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 72 18May 201511. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4. Dynamic International Prognostic Scoring System (DIPSS) for Primary 
Myelofibrosis
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 74 18May 2015Appendix 2. Study Procedures Table
Assess mentScreening 
(-
28to -
21Days)Baseline  
(-7 +/ -2 
Days) EnrollmentWeek 
2 
(+/-3 
days)Week 4 
(+/-3 
days)Week 8 
(+/-3 
days)Week 12 
(+/-3 
days)Week 16 
(+/-3 
days)Week 20 
(+/-3 
days)Week 24 
(+/-7 
days)Early Study 
Drug 
Discontinuation30 Day 
Follow -
Up
Informed c onsent X
Medication and 
medical h istoryX
Transfusion 
RecordingX X X X X X X X X X X X
Physical exam and 
myelofibrosis 
symptoms assessmentX X X X X X X X X X X X
DIPSS Assessment X
Vital Signs X X X X X X X X X X X
AEs, Concomitant 
MedicationsX X X X X X X X X X X
Ophthalmic 
examinationX X X
MMB accountability 
and dispensingg X X X X X X X X
MMB dosing at site X X X X X X X X
Patient Reported Outcomes
Modified MPNSAF 
TSS----------------------------------------------------------------- Daily ---------------------------------------------------------------  X
PGIC X X
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 75 18May 2015Assess mentScreening 
(-28 to -
21Days)Baseline  
(-7 +/ -2 
Days) EnrollmentWeek 
2 
(+/-3 
days)Week 4 
(+/-3 
days)Week 8 
(+/-3 
days)Week 12 
(+/-3 
days)Week 16 
(+/-3 
days)Week 20 
(+/-3 
days)Week 24 
(+/-7 
days)Early Study 
Drug 
Discontinuation30 Day 
Follow -
Up
Laboratory Assessments
Viral Hepatitis B and 
CX
Chemistry X X X X X
CBC with differential, 
reticulocyte countX X X X X X X X X X X
Thiamine status X X X
Erythropoietin X X X
C-Reactive Protein 
(CRP)X X X X X X
Urinalysis X X X X X X X X X
Serum pregnancy testaX
Urine pregnancy test X X X X X X X X
Biom arker Samples
Bone marrow biopsy 
& aspi[INVESTIGATOR_409747] X
Buccal Swab X
Spleen & LIC MRI X X X
Iron Studies X X X X X X X X X
Hepcidin X X X X X X X X X
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 76 18May 2015Assess mentScreening 
(-28 to -
21Days)Baseline  
(-7 +/ -2 
Days) EnrollmentWeek 
2 
(+/-3 
days)Week 4 
(+/-3 
days)Week 8 
(+/-3 
days)Week 12 
(+/-3 
days)Week 16 
(+/-3 
days)Week 20 
(+/-3 
days)Week 24 
(+/-7 
days)Early Study 
Drug 
Discontinuation30 Day 
Follow -
Up
JAK2V617F allele
burden and other 
mutation testsX X X
Pharmacodynamicsc,dXdX X
PharmacokineticseX X X
Cytokines /chemokines X XfX X X X X X
Exploratory signaling 
(mass cytometry)X X X X
CD34+Cell Count X X X X
Gene expression X X X X
Immunophenotype 
(flow cytometry)X X X X
a For female subject post -menopausal for less than two years, if FSH 40 mIU/ mL a serum pregnancy test will be required
b Hepcidin sample collection will occur at the following times: Baseline Visit:, between 8am-and 10 am, 6 hours later; Enrollment , Weeks 4, 8, 12, 16, 20, and 24 predose
(between 8 am and 10 am) and 6 hours postdose
c P harmacodynamics biomarker sample collection will occur at the following tim es: predose , 2, 4, and 6 hours postdose at Enrollment, then Weeks 4 and 24. 
d Additional e xploratory pharmacodynamics sample collection will occur at the following times: predose , and 2hours postdose at Enrollment only. 
e PK sample collection at the following times: predose , 2, 4, and 6 hours postdose at Enrollment, then Week s4 and 24.
f Cytokine sample collection times at enrollment: predose, 6 hours postdose. All other time points: predose only.
g MMB accountability ONLY at Week 24 and ESDD visits
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 77 18May 2015Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1.Pregnancy and Contraception Requirements for Males and Females of Childbearing 
Potential 
The risks of treatment with momelotinib (MMB) during pregnancy  have not been evaluated. 
Data available at this time suggest that this drug does not have a drug -drug interaction (DDI) 
with hormones used for contraception. Please refer to the latest version of the investigator’s 
brochure for additional information.
2.Definition of Female of Childbearing Potential
For the purposes of this study , a female 
subject of childbearing potential is a nonmenopausal 
female who has not had a hy sterectom y, bilateral oophorectom y, or medically  documented 
ovarian failure. This definition includes a pubertal female who has not y et started menstruating. 
A woman who has had a tub al sterilization is considered to be of childbearing potential.
A female subject may  be considered m enopaus alineither of the following conditions:
Surgical menopause: Appropriate medical documentation of prior complete bilateral 
oophorectom y (ie, surgica l removal of the ovaries and occurring at the age at which the 
procedure was performed)
Spontaneous menopause: Permanent cessation of previously occurring menses as a result of 
ovarian failure with documentation of hormonal deficiency  by a certified health care 
provider . The worldwide mean age of spontaneous menopause is 49.24 (SD 1.73) years
A hormonal deficiency  should be properl y documented in the case of suspected spontaneous 
menopause as follows:
If age 54 years and with the absence of normal menses: serum follicle stimulating hormone 
(FSH) level elevated to within the postmenopausal range based on the laboratory  reference 
range where the hormonal assay  is performed
If age <54 years and with the absence of normal menses: negative serum or urine human 
chorionic gonadotropin (hCG) with concurrently  elevated serum FSH level in the 
postmenopausal range, depressed estradiol (E2) level in the postmenopausal range, and 
absent serum progesterone level, based on the laboratory  reference ranges where the 
hormonal assay s are performed
3.Contraceptive Requirements 
Male subjects and female subjects of childbearing potential who engage in intercourse must 
agree to utilize protocol specified methods of contraception from the s creening/ enrollment visit 
throughout the stu
dy period and, for male subjects for [ADDRESS_516811] dose of MMB . 
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516812] provide periodic confirmation of 
continued abstinence from heterosexual intercourse and regular pregnancy testing while taking 
MMB . The investigator will counsel subjects on the protocol specified method(s) for avoiding 
pregnancy  in case the subject choose s to engage in heterosexual intercourse. See 
Appendix Table 1for the protocol specified contraceptive methods.
If tubal sterilization is via the Essure procedure, verification of tubal blockage b y 
hysterosalpi[INVESTIGATOR_8913] (HSP) must be performed approximately  [ADDRESS_516813] discontinue nursing before MMB administration.
Appendix Table 1. Protocol Specified Contraceptive Methods
Methods to Use by [CONTACT_409767]
(choose one and use with a barrier 
method)Barrier Methods
(choose one and use with a hormone 
method)
Intrauterine Devices (IUDs)
Copper T 380A IUD
LNg 20 IUD
Tubal SterilizationEstrogen and Progesterone
Oral contraceptives
Transdermal patch
Vaginal ring
Progesterone
Injection
ImplantDiaphragm with spermicide
OR
Cervical cap with spermicide
 Male condom (with or without 
spermicide)
Partner’s vasectomy must be used with a hormone or barrier method.
The investigator will counsel all subjects on the most effective method(s) for avoiding pregnancy  
during the stud y.
4.Additional Requirements for Male Subjects
Male subjects must agree to use condoms during heterosexual intercourse and avoid sperm 
donation while enrolled in the study  and for at least [ADDRESS_516814] dose 
of MMB .
Mom elotinib (MMB)
Protocol GS -US-352-[ADDRESS_516815] report the information to the investigator.
Instructions for reportin g pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section 7.7.
Mom elotinib (MMB)
Protocol GS -US-352-1672 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 80 18May 2015Appendix 4. Dynamic International Prognostic Scoring System (DIPSS) for 
Primary Myelofibrosis
Prognostic variableValue
0 1 2
Age ≤ 65 > 65
WBC ≤25 > 25
Hgb ≥10 < [ADDRESS_516816] < 1 ≥ 1
Constitutional symptoms No Yes
The risk category  is obtained by  [CONTACT_190960].
Risk categori esare defined as:
Low: 0
Intermediate -1: 1 or 2
Intermediate -2: 3 or 4
High: > 4
{[ZIP_CODE]}